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                                                        ABSTRACT 
The endoplasmic reticulum is the primary organelle in the cell which has the 
responsibility of properly folding proteins belonging to the secretory pathway. Secretory 
proteins are essential for a variety of functions within the body like metabolism, growth 
and survival. Hence, proper folding of the proteins in the ER is absolutely essential to 
maintain cellular and body function. The environment of the ER is substantially different 
from that of the cytoplasm and is primed essentially to provide the optimum conditions to 
fold newly synthesized polypeptides following translation by the ribosomes in the 
cytoplasm and on the surface of the ER. 
In order for secretory proteins to fold properly, ER homeostasis must be 
maintained. ER homeostasis is defined by the dynamic balance between the ER protein 
load and the ER capacity to process this load. The optimum environment of the ER, or 
ER homeostasis, can be perturbed by pathological processes such as hypoxia, glucose 
deprivation, viral infections, environmental toxins, inflammatory cytokines, and mutant 
protein expression, as well as by physiological processes such as aging. Disruption of ER 
homeostasis causes accumulation of unfolded and misfolded proteins in the ER. This 
condition is referred to as ER stress. Cells cope with ER stress by activating the unfolded 
protein response (UPR).  
The UPR is initiated by three ER transmembrane proteins: Inositol requiring 1 
(IRE1), PKR-like ER kinase, and activating transcription factor 6 (ATF6). These three 
master regulators sense and interpret protein folding conditions in the ER and translate 
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this information across the ER membrane to activate downstream effectors, spliced 
XBP1, phosphorylated eIF2α and ATF4, and cleaved active ATF6 respectively. These 
effectors have two distinct outputs, homeostatic and apoptotic. Homeostatic outputs are 
adaptive responses that function to attenuate ER stress and restore ER homeostasis. These 
responses include the attenuation of protein translation to reduce ER workload and 
prevent further accumulation of unfolded proteins, upregulation of molecular chaperones 
and protein processing enzymes to enhance the ER folding activity, and the increase in 
ER-associated degradation (ERAD) components to promote clearance of unfolded 
proteins. When ER stress reaches a point where the cells cannot tolerate the load of 
unfolded proteins any more, apoptosis sets in. 
One of the major secretory proteins in mammals, vascular endothelial growth 
factor VEGF, is essential for either normal or pathological angiogenesis (blood vessel 
development). VEGFA is the primary member of this family which is expressed in all 
endothelial cells and is responsible for sprouting and invasion of blood vessels into the 
interstitium and thus helps in supplying nutrients and oxygen to growing cells. Recent 
studies have indicated that cells suffering from insufficient blood supply experience ER 
stress. The ER needs energy and oxygen for the folding process, thus nutrient deprivation 
(low ATP production) and hypoxia caused by insufficient blood supply leads to 
inefficient protein folding and ER stress in cells, especially in cancer cells that grow and 
spread rapidly. This condition also occurs in the development of the mammalian placenta. 
The placenta is an essential tissue characterized by a lot of blood vessels. It is responsible 
for the exchange of nutrients and growth factors between maternal and fetal blood vessels 
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and hence is essential for survival of the embryo. Nutrient deprivation and hypoxia 
stimulate the production of VEGFA and other angiogenic factors, leading to protection 
against ischaemic injury in both cancer cells as well as the developing placenta.  
In this dissertation, we report that the three master regulators of the UPR, IRE1α, 
PERK and ATF6α, mediate transcriptional regulation of VEGFA under ER stress in 
cancer cells. Inactivation of any of the three master regulators leads to attenuation of 
VEGFA expression under ER stress. We show that IRE1α is able to regulate VEGFA 
through its downstream transcription factor XBP1 which activates the VEGFA promoter. 
IRE1α mediated VEGFA regulation is also essential for normal development of 
labyrinthine trophoblast cells in the placenta. ATF6α also regulates VEGFA via its 
promoter. PERK is able to activate VEGFA by preferential activation of its downstream 
effector, ATF4, which binds intron 1 of the VEGFA gene. Thus our work reveals a two-
pronged differential regulatory action of the UPR sensors on VEGFA gene expression. 
This work suggests that a fully active UPR is essential for VEGFA upregulation 
under ER stress. All three regulators are required in cancer cells for normal VEGFA 
expression. This tight regulation of VEGFA by the UPR presents a wonderful 
opportunity for therapeutic intervention into angiogenic growth of tumors. 
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The endoplasmic reticulum (ER) is the primary cellular organelle responsible for 
proper folding of secretory proteins, which are essential for critical functions in the body 
like the insulin hormone and blood vessel growth factor, VEGF. Defects in the folding 
properties of the ER due to overload of proteins or harsh environmental conditions causes 
‘ER stress’, which can lead to activation of the unfolded protein response (UPR) 
signaling pathway in the ER. One of the UPR’s functions is to upregulate certain genes 
that are crucial for cell survival and homeostasis. This thesis focuses on the relationship 
between the UPR signaling and VEGF expression and the mechanism of VEGF 
upregulation under ER stress. 
1.1. The endoplasmic reticulum and ER stress 
 The endoplasmic reticulum (ER) is the first compartment of an ordered 
membranous network called the secretory pathway, which is responsible for the 
synthesis, modification and delivery of biologically active proteins to their proper target 
sites within the cell and to the extracellular matrix. The ER has essential roles in multiple 
cellular processes including calcium homeostasis, protein folding and secretion and lipid 
biosynthesis, which are required for cell survival and normal cellular functions (1). It is 
responsible for the early steps of folding of nascent polypeptides, post-translational 
modifications and prevention of aggregation during maturation of secretory proteins. This 
is achieved by the action of ER-resident chaperones, oxidoreductases and degradative 
enzymes (2). 
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The lumen of the ER has unique chemical and biological features and provides a 
different environment than the cytosol.  Proteins that are scheduled for transport out of 
the cell in their mature active conformations enter the ER through a hydrophobic signal 
sequence co-translationally with the help of ER- membrane bound ribosomes. Signal 
peptidases cleave this sequence and then the nascent proteins interact with ER resident 
molecular chaperones. This interaction depends on Ca2+ ions and the ER is the major site 
for Ca2+ storage in mammalian cells. ER-luminal Ca2+ concentrations reach 5 mM, 
compared to 0.1 μM in the cytosol. This is due to active transport by Ca2+-ATPases. ER 
Ca2+ concentrations change rapidly during normal molecular signaling as several 
enzymes depend on Ca2+ for their proper functions. Ca2+ helps in protein-protein 
interaction and can alter hydrophobic interactions thereby helping in folding proteins. 
The ER is rich in molecular chaperones like the immunoglobulin heavy-chain binding 
protein BiP, (also known as glucose-regulated protein, 78kDa (GRP78)), GRP94, 
calnexin and calreticulin which help stabilize protein-folding intermediates. Perturbation 
of ER-luminal Ca2+ inhibits chaperone function (2).   
Glutathione is a major redox buffer in the cell. Its reduced to oxidized ratio in the 
cytoplasm is more than 50:1. However, in the ER this ratio drops to 1:1 to 3:1. The 
presence of an oxidizing environment inside the ER as compared to the cytosol helps in 
stabilization and maturation of proteins by forming disulfide bonds. This is mediated by 
protein disulfide isomerase (PDI) that utilizes reducing equivalents in the ER thereby 
promoting oxidative stress. PDI is kept in an oxidized state by endoplasmic reticulum 
oxidoreductin-1 (ERO1) which is an FAD-dependent oxidase. Molecular O2 is the final 
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electron acceptor which directly oxidizes ERO1. Hence, removal or disruption of O2 
supply can result in stopping this cascade and can also generate reactive oxygen species, 
which is not ideal for protein folding and can result in accumulation of unfolded proteins 
(3). 
 The ER is also the site of other post-translational modifications like glycosylation 
of proteins. Attachment of asparagine-linked oligosaccharide moieties to many proteins 
entering the ER helps to increase their solubility, provides stability and serves as a signal 
of the protein’s folding state. This is accomplished by the calnexin-calreticulin cycle, 
which retains non-native glycoproteins in the ER until they are correctly folded and also 
helps to degrade misfolded glycoproteins (4).  
Having all these unique properties, the ER is able to act as a protein folding 
factory that has a robust system of quality control on its products in order to ensure that 
only properly folded, mature and functional proteins reach their destinations out of the 
secretory pathway. Since the fate of various intracellular as well as extracellular functions 
depend on these properly folded proteins, the ER activity becomes vital for cell survival 
as downstream organelles are not optimized for protein folding activity. The ER is able to 
do all these functions with the help of molecular chaperones, folding enzymes and 
oxidoreductases. The chaperones include the heat shock protein HSP70 family member, 
BiP, that binds to nascent polypeptides to form a complex which helps in folding them. 
Other important chaperones are GRP94, the HSP40 family and peptidyl-prolyl 
isomerases. Calnexin and calreticulin are important folding enzymes that interact with 
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nascent proteins that carry monoglucosylated N-linked glycans. Others include ER 
degradation-enhancing alpha mannosidase-like protein (EDEM), HERP and co-
chaperones SIL1 and P58IPK (4).  Finally, thiol-disulfide oxidoreductases like PDI help in 
oxidation, isomerization and reduction of disulfide bonds in the secondary and tertiary 
structure of nascent proteins and help them to reach their final conformation within the 
ER (4). 
With the help of these unique conditions and folding machinery, the ER is able to 
maintain a strict control over balance or homeostasis in the cell. However, the load of 
proteins on the ER can easily vary depending on environmental conditions. A variety of 
conditions such as alteration in luminal redox balance, nutrient deprivation, changes in 
Ca2+ homeostasis, hypoxia, elevated protein synthesis as well as mutant protein synthesis 
lead to accumulation of unfolded or aggregated proteins in the ER. When this influx of 
unfolded polypeptides exceeds the folding and processing capacity of the ER, it disrupts 
the ER homeostasis and causes ‘ER Stress’(2, 5). Cellular redox regulation is affected by 
hypoxia, reactive oxygen species and reducing agents, which in turn interfere with 
disulfide bonding of proteins within the lumen of the ER thereby promoting accumulation 
of misfolded or unfolded proteins. Glucose deprivation is an example of nutrient 
deprivation that can disrupt N-linked glycosylation in the ER and causes ER stress. 
Disruption of Ca2+ homeostasis in the ER contributes to accumulation of unfolded 
proteins by blocking the activity of calcium-dependent enzymes like GRP94 and 
calreticulin (2, 4). Apart from the environmental disturbances that cause accumulation of 
unfolded proteins, some genetic disorders where mutations occur in genes encoding 
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membrane and secretory proteins can lead to improper folding in the ER and thus the 
unfolded proteins are stuck within the compartment. One example is the Z variant of α1 
antitrypsin inhibitor, a folding mutant that remains in the ER of hepatocytes rather than 
go to the lung where it normally functions (6). Viral infection can also overload the ER 
with virus-encoded proteins thereby causing ER stress. All these different insults can 
change the folding capacity of the ER, which if left unchecked, can prove to be fatal for 
the cell.  
1.2. Unfolded protein response signaling 
To cope with the unfavorable ER stress conditions, an ER-to-nucleus signaling 
pathway called the unfolded protein response (UPR) is activated to reverse the stress. The 
UPR was first discovered in the 1970s, when analysis of virus-transformed mammalian 
cells found GRP78 and GRP94 as proteins inducible by glucose starvation (7). 
Subsequent studies in yeast and mammalian cells in the 1990s revealed an entire 
signaling mechanism devoted to the proper folding and secretion of functional proteins in 
the ER. The UPR has been shown to be induced by physiological fluctuations during 
differentiation and development of secretory cells (e.g., antibody secreting plasma cells, 
pancreatic β-cells), infection, and by mutations in secretory and transmembrane proteins. 
Activation of UPR results in upregulation of genes encoding proteins like ER-resident 
chaperones and protein modifying enzymes which help the proteins to fold.  The ER is 
also able to clear the unfolded protein load by exporting proteins to the proteasome in  the 
cytosol for degradation via the ER-associated degradation (ERAD) system (8, 9). In 
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addition, activation of the UPR results in a down regulation of general protein synthesis. 
This reduces the influx of new proteins into the ER while the UPR is activated (10). Thus 
both transcriptional and translational signals from the stressed ER help to restore the ER 
homeostasis and maintain the normal physiology of professional secretory cells like 
pancreatic β cells, hepatocytes and plasma cells all of which have a well-developed 
extensive ER structure. In some cases, the UPR can activate signal cascades associated 
with innate immunity and host defense mechanisms like mitogen-activated protein 
kinases (MAPKs), jun N-terminal kinase (JNK) and p38MAPK and the transcription 
factor nuclear factor-κB (NFκB) (1). However, if homeostatic balance is not restored 
even after UPR induction, the cell might undergo apoptosis. ER stress induction involves 
both caspase-dependent apoptosis as well as caspase-independent necrosis (11). ER stress 
can also induce autophagy which is associated with non-apoptotic cell death and 
promotes survival (12).  The three major ER-resident transducers of the UPR are: inositol 
requiring 1 (IRE1), activating transcription factor 6 (ATF6) and PKR-like ER kinase (13) 
(13) (Figure 1.1). 
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1.2.1. IRE1 
IRE1 is a primary ER stress sensor which is evolutionarily conserved among all 
eukaryotes. It was first identified in yeast in a screen for mutants defective in 
phosphatidylinositol biosynthesis and required high concentrations of inositol for growth 
and hence named inositol-requiring 1 (IRE1) (14). It also acted as an unfolded protein 
sensor in the ER membrane and was essential for survival under ER stress (14, 15). 
Accumulation of unfolded proteins in the ER activates IRE1 protein which in turn 
uniquely splices an intron of the downstream effector HAC1 mRNA in the cytosol (16-
19). Activation of IRE1 in yeast is thought to be a two-step process. Under normal 
conditions the ER chaperone BiP is associated with luminal domain of yeast IRE1. When 
ER stress occurs, BiP dissociates from IRE1 in response to the presence of unfolded 
proteins, leading to dimerization and cluster formation. In the second step, unfolded 
proteins directly interact with the stress-sensing domain and orient the IRE1 cluster to an 
active conformation with full ribonuclease activity (20, 21).The resulting exons are fused 
by tRNA ligase to form a spliced mRNA which is translated into a potent transcription 
factor, HAC1 which upregulates UPR target genes in yeast (22). BiP binding of IRE1 
luminal domain therefore has a repressive effect on IRE1 signaling pathway and acts as a 
negative regulator. Recently, a novel negative regulator of IRE1 signaling was 
discovered. A scaffold protein known as a receptor for activated C-kinase 1(RACK1) was 
shown to interact with IRE1 in a complex with protein phosphatase 2A (PP2A) to 
promote dephosphorylation of IRE1 and hence its inactivation under high glucose-
stimulated ER stress conditions (23). 
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Mammalian IRE1 gene has two forms, IRE1α and IRE1β. IRE1α is ubiquitous 
whereas IRE1β is expressed in intestinal epithelial cells (24-26). IRE1α is essential for 
normal development as mutants are embryonic lethal by d12.5 whereas IRE1β deletion 
does not cause any significant defects (26, 27). In mammals, the N-terminal luminal 
domain is also associated with the chaperone BiP (GRP78) under normal conditions. But 
the mammalian IRE1 luminal domain does not interact with unfolded proteins directly as 
seen in yeast, and it is the dissociation of  BiP under ER stress conditions that activates 
mammalian IRE1 (28-30). The C-terminal domain of IRE1 has two enzymatic activities, 
a kinase and an endoribonuclease. Upon oligomerization, the kinase domains come in 
contact and trans-autophosphorylate each other. This autophosphorylation activates the 
RNase  domain to cleave a specific 26-nucleotide intron from the XBP1 mRNA, 
encoding the metazoan ortholog of HAC1(31, 32). Ligation of cleaved XBP1 mRNA 
shifts the open-reading frame resulting in the conversion of  the 267 amino acid unspliced 
XBP1 protein to a 371 amino acid potent transcription factor called XBP1s where ‘s’ 
indicates spliced form (31-33). Spliced XBP1 has a role in upregulation of a broad 
spectrum of UPR genes which are involved in protein folding, entry into the ER, ER-
associated degradation (ERAD) and protein quality control (34, 35).  
IRE1α has other important cellular functions in addition to splicing XBP1 mRNA. 
The cytosolic domain of IRE1α can bind to the adaptor protein TNF receptor-associated 
factor 2 (TRAF2) under prolonged ER stress conditions. This in turn activates apoptosis 
signal-regulating kinase 1 (ASK1) and the cJun-N terminal kinase (JNK) pathway, which 
signal apoptosis under irreversible ER stress (27). IRE1α has been found to play a role in 
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autophagy. ER stress conditions upregulate autophagy via the IRE1α –JNK signaling 
mechanism to eliminate damaged organelles and aggregated proteins (12). IRE1α has 
also been implicated to have a role in the degradation of mRNAs encoding proteins in the 
ER which were difficult to fold. This was first described in the fruit fly, D. melanogaster 
where the authors found that a select number of mRNAs were downregulated under ER 
stress in an IRE1α–dependent manner. This was mediated by the endoribonuclease 
domain of IRE1α and is independent from XBP1 activity (36). A model proposed by the 
authors suggested that the selective degradation of certain mRNAs was related to the 
secretory propensity of the proteins being encoded by the degraded mRNA. IRE1α-
dependent mRNA degradation also occurs in mammalian cells. ER stress has a role in the 
degradation of insulin mRNA, thereby, reducing proinsulin protein levels in pancreatic β 
cells (37). Interestingly, XBP1 mRNA splicing and ER stress-mediated mRNA decay are 
distinct separable functions of IRE1α. XBP1 mRNA splicing could be reproduced by 
artificially dimerizing IRE1α to activate the RNase using an allosteric mechanism. But 
the mRNA degradation activity required IRE1α dimerization and autophosphorylation by 
ER stress (38, 39). These data showed that decay of ER localized mRNAs encoding 
proteins which are difficult to fold promote cell survival. In contrast, degradation of 
mRNAs encoding chaperones promotes apoptosis. Thus IRE1α has a dual function in ER 
stress response: a) regulating adaptation to stress and cell survival by the controlling 
XBP1-s expression as well as ER secretory protein mRNA decay and b) activation of 
apoptosis under severe ER stress conditions through the ASK1/JNK pathway and mRNA 
decay of ER chaperones.  
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Spliced XBP1 (XBP1s), a basic leucine zipper (bZIP) transcription factor forms 
the homeostatic arm of IRE1α under ER stress conditions as explained above. XBP1s is 
believed to bind the GACGTG box which comprises the unfolded protein response 
element (UPRE) with a highly conserved ACGT core (40, 41) or the CCACG box which 
is part of the composite ER stress response element (ERSE) in the promoters of its target 
genes which include XBP1 itself (42). A genome-wide profiling approach has revealed a 
link between XBP1 and cell differentiation, signaling and DNA damage repair pathways 
in a cell and tissue type-specific manner (42). XBP1s regulates the expansion of the 
secretory pathway by controlling ER/Golgi biogenesis and phospholipid biosynthesis (35, 
43). XBP1s also heterodimerizes with ATF6α to induce proteins involved in ER-
associated degradation of misfolded proteins (44). Interestingly, the unspliced form of 
XBP1 protein, XBP1u, has been shown to have a role in suppression of XBP1s activity 
once ER stress has subsided. XBP1u has a ‘degradation domain’, which is absent in the 
XBP1s protein. When ER stress is relieved and IRE1α is no longer active, the remaining 
XBP1 spliced protein in the nucleus can still help in transcription of XBP1 mRNA but no 
splicing occurs, leading to accumulation of XBP1u. XBP1u  then forms a complex with 
XBP1s and is transported to the proteasome for degradation thus acting as a negative 
feedback regulator of XBP1s (45). XBP1u (unspliced) protein also has a role in targeting 
the XBP1 mRNA to the ER membrane where IRE1α protein is located to facilitate 
IRE1α-mediated splicing (46).  
Xbp1-/- mice are embryonic lethal and suffer from severe liver hypoplasia and 
anemia which can be attributed impaired activation of UPR in the hepatocytes, which are 
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the site of synthesis of various serum secretory proteins (13). Studies have shown that it 
is required for cardiac myogenesis, hepatogenesis, plasma cell differentiation and 
development of secretory tissues. XBP1s controls many of the components of the ER 
associated degradation (ERAD) pathway, which maintains ER quality control. XBP1s 
expression and thereby the ERAD is affected by the proteasome inhibitor, velcade, which 
is used for treating multiple myeloma (47). Studies have shown that Xbp1+/- animals 
show impaired glucose homeostasis and are predisposed to diet-induced insulin resistance 
and type 2 diabetes because of impaired insulin receptor signaling in these animals (48). 
Specific deletion of XBP1 in immune cells blocks the terminal differentiation of B cells 
into antibody-secreting plasma cells (49). All these reports suggest that XBP1 is an 
important molecule that is involved in metabolism and energy expenditure, cell survival 
and differentiation, and proper ER function. Recently, it has also been linked to genes 
associated with neuro and myodegenerative disorders like Alzheimer’s disease and 
inclusion body myositis (IBM)(42).  
1.2.2. PERK 
Double-stranded RNA-activated protein kinase (50)-like endoplasmic reticulum 
kinase (13) is another primary ER stress sensor (13). Also known as EIF2AK3 or 
pancreatic eIF2α kinase (PEK), it is an ER-resident transmembrane protein ubiquitously 
expressed but highly enriched in secretory cells like pancreatic β cells. It is a member of a 
family of eukaryotic initiation factor (eIF2) kinases that reduce global protein translation 
in response to specific stress signals. 
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The eIF2 complex is an integral part of protein synthesis in all eukaryotes because 
it recruits the initiator methionyl tRNA to ribosomes about to begin protein translation. 
Phosphorylation of serine-51 on the α-subunit of eIF2 complex inhibits this activity and 
thus globally reduces protein translation. eIF2 is a translation factor that has three 
subunits (α to γ) that combines with Met-tRNAMet and GTP to form the translation 
initiation complex with the ribosome. Before joining the small and large ribosomal 
subunits, the GTP is hydrolyzed to GDP to release the initiation factor. To initiate 
subsequent rounds of translation, the guanine nucleotide exchange factor, eIF2B, 
converts the inactive GDP-eIF2 to active GTP-eIF2. eIF2B is a complex exchange factor 
with two catalytic subunits (ε/γ) and three regulatory subunits (δ/β/α), which bind as a 
complex to phosphorylated eIF2α thereby reducing eIF2B function (50, 51). 
Phosphorylation of eIF2α is carried out by a family of kinases that possess 
homologous catalytic domains but different stress-sensitive regulatory domains. These 
eIF2α kinases include heme-regulated inhibitor (HRI or EIF2AK1), which is induced by 
hemoglobin deficiency and oxidative stress in erythroid tissues (52), dsRNA-activated 
protein kinase (PKR or EIF2AK2) which has a role in antiviral defense mechanism in 
conjunction with interferons (53), GCN2 (EIF2AK4), is activated in response to nutrient 
amino acid deprivation (54) and of course PERK which is activated in response to ER 
stress (55, 56). 
PERK is a type 1 ER transmembrane protein that is highly enriched in 
professional secretory cells and shares similar amino-terminal regulatory domains in the 
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ER lumen as IRE1. In fact, the sequences of the sensing domains of IRE1α and PERK are 
similar and these luminal domains are interchangeable. The resulting chimeric protein is 
functional and activates the UPR upon ER stress induction (57). PERK is also activated 
by dimerization in response to ER stress. It has been shown that fusion of the 
dimerization domain of PERK facilitates constitutive PERK autophosphorylation and 
eIF2α kinase activity (58). Conversely, deletion of dimerization domain prevents 
autophosphorylation in response to ER stress (59). 
Research in Dr. David Ron’s lab in the year 2000 showed that PERK is associated 
with the ER chaperone BiP/GRP78 in the absence of stress, similar to IRE1 (60). ER 
stress leads to the accumulation of unfolded proteins in the ER, which competes for BiP, 
resulting in its dissociation from PERK.  This stimulates the dimerization and 
autophosphorylation of PERK. This mechanism is dynamic, as removal of ER stress 
leads to swift reassociation of PERK with BiP and its dephosphorylation. Thus, this 
mechanism of activation seems to be conserved between PERK and IRE1 (60). Though a 
detailed crystallographic study of the mechanism of luminal domain binding and 
activation has not been reported yet for mammalian PERK, its similarity and sequence 
homology to IRE1 suggests that it follows a similar mode of activation. However, IRE1 
itself seems to have different modes of activation in yeast (via oligomerization and direct 
binding to unfolded proteins) and in mammals (dimerization only after BiP release and 
no association with unfolded protein) (20, 30) and hence this subject is still under 
investigation for PERK. 
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The importance of translational regulation is revealed in Perk-/- mice and in 
humans suffering from a rare genetic disease, Wolcott-Rallison syndrome that is 
characterized by neonatal or early-infancy insulin-dependent diabetes, exocrine pancreas 
atrophy, skeletal dysplasia and growth retardation (61, 62). These mice are born with 
essentially normal pancreatic islets with a normal capacity for insulin production and 
secretion. However, there is progressive pancreatic islet β-cell death highlighting the 
importance of PERK in the proliferation and differentiation of insulin-secreting β-cells 
during fetal development. In animals lacking PERK, the new proteins continue to enter 
the ER as there is no eIF2α phosphorylation to limit protein synthesis. This causes 
accumulation of unfolded proteins and excessive ER stress signaling which ultimately 
causes cell death (56, 62). 
Phosphorylation of eIF2α not only causes attenuation of protein translation which 
is the primary phase of PERK activity, but also leads to activation of a transcription 
factor, activating transcription factor-4 (ATF4). This forms a second phase of enhanced 
expression of UPR genes after the initial repression of translation. While most RNA 
transcripts experience decreased translation because of eIF2α phosphorylation by PERK, 
ATF4 mRNA is translated more efficiently (63). This mode of translational control of 
expression under ER stress is due to the presence of two upstream open reading frames 
(uORFs) in the 5’-leader of ATF4 mRNA. The second uORF is inhibitory and is out of 
frame overlapping the true ATF4 coding sequence. ATF4 translation begins at the 5’-end 
of uORF1 under normal resting conditions with the eIF2/GTP/Met-tRNA ribosomal 
initiation complex scanning the ATF4 mRNA. After translating uORF1, as eIF2-GTP is 
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present and eIF2α phosphorylation is low, the ribosomal complex rapidly reinitiates 
translation from uORF2. It is proposed that after translation of uORF2, the ribosome 
dissociates from ATF4 mRNA and hence there is reduced ATF4 expression. Under ER 
stressed conditions, elevated eIF2α phosphorylation reduces the eIF2-GTP complex. The 
limited levels of the initiation factor cause delayed reinitiation and help the ribosome to 
bypass the uORF2 and instead reach the ATF4 initiation codon. By this time the 
ribosome reacquires the eIF2-GTP/Met-tRNA complex and initiates ATF4 translation. 
Hence, ER stress causes the initiation complex to ‘skip’ the inhibitory uORF2, thereby 
rapidly elevating ATF4 protein levels (64, 65).  
A gene expression microarray analysis of Perk-/- and Atf4-/- cells treated with the 
ER stress inducer, tunicamycin, which blocks N-linked glycosylation of proteins in the 
ER, revealed the impact of PERK and ATF4 on a wide variety of functions (66). The 
genes regulated by PERK are involved in folding and processing of secretory proteins, 
the ERAD pathway for clearance of misfolded proteins, glutathione biosynthesis 
controlling the cellular redox status, amino acid synthesis and transport, regulation of 
apoptosis and transcriptional regulation. ATF4 controlled genes formed only a subset of 
the genes controlled by PERK with significant roles in amino acid metabolism, protection 
from oxidative stress, regulation of apoptosis and increased expression of bZIP 
transcription factors, ATF3 and CHOP (66). ATF4 can form homodimers or 
heterodimerize with several bZIP transcription factors such as C/EBP isoforms, FOS, 
JUN and NRF2, to form elaborate transcriptional machinery that responds to different 
kinds of cellular stress, ER stress being one of them. Different upstream eIF2α kinases 
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can induce ATF4 transcription under different types of stress. ATF4 then associates with 
other transcription factors that are specific to each stress condition and independent of 
eIF2α phosphorylation and induces transcription of effector genes required to mitigate 
that stress. For example, ER stress activates PERK, whereas amino acid deficiency 
activates GCN2, both of which are upstream eIF2α kinases which can activate ATF4. 
Under ER stress conditions, ATF4 functions in combination with the bZIP transcription 
factors XBP1 and ATF6 to direct the UPR. However, under amino-acid deficiency, ATF4 
works together with ATF2, which is phosphorylated and activated by mitogen-activated 
protein kinases (MAPKs) (67). It should be noted that mutations of the other known 
eIF2α kinases (PKR, GCN2 and HRI) do not result in mice with diabetes, thus showing 
the importance of ER stress mediated eIF2α phosphorylation for this phenotype (68-70). 
ATF4 function has been mainly studied in the context of amino acid deprivation 
and oxidative stress- induced signaling. One of the best characterized promoters activated 
by ATF4 is asparagine synthetase (ASNS), which catalyses the biosynthesis of 
asparagine from aspartate. This promoter has two cis-acting elements designated as 
nutrient-sensing response element (NSRE)-1 and 2 which are also known as amino acid 
response elements (AARE). ATF4 binds the NSRE-1 in response to ER stress or amino 
acid deficiency (71) and recruits ATF3 and C/EBPβ in a complex two-step mechanism to 
drive ASNS transcription (72). This mechanism is thought to occur in most of the other 
ATF4-targeted promoters, like ATF3, CHOP and VEGF, which are induced by amino 
acid deficiency and the UPR. CHOP is a proapoptotic transcription factor which causes 
cell death under high levels of ER stress. Chop-/- animals are resistant to the renal toxicity 
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by ER stress inducer, tunicamycin. CHOP directly activates another important target of 
ATF4, GADD34, which serves as a regulatory subunit of the type 1 serine/threonine 
phosphatase, PP1 that dephosphorylates eIF2α. This forms a feedback control of the 
PERK-eIF2α kinase pathway to restore synthesis of those proteins that help to keep the 
processing capacity of the ER intact after the UPR is established (73, 74). Mammalian 
cells also have a constitutive repressor of eIF2α phosphorylation, CreP, which is also a 
regulatory subunit of PP1 (75). Another negative regulator of PERK activity is the Hsp40 
family member P58IPK. ER stress activates P58IPK transcription through an ER stress 
mediated response element (ESRE) in its promoter. P58IPK inhibits PERK-mediated 
eIF2α signaling leading to attenuation of the UPR and hence is important for the recovery 
phase (76). 
1.2.3. ATF6 
The third arm of the unfolded protein response pathway comprises the type II ER 
transmembrane protein, activating transcription factor-6 (ATF6), which encodes a basic 
leucine zipper (bZIP) transcription factor in its cytoplasmic domain. Mammalian ATF6 
consists of two homologous proteins, ATF6α and ATF6β. Under normal conditions, 
ATF6 remains attached to the ER membrane by a transmembrane segment and its C-
terminal stress-sensing domain projects into the ER lumen. Under ER stress conditions, 
ATF6 translocates from the ER to the Golgi complex where it is first cleaved by S1P (site 
1 protease) in the luminal domain. The N-terminal membrane-anchored half is then 
cleaved by the metalloprotease site-2 protease (S2P) within the phospholipid bilayer. This 
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releases the cytosolic  bZIP DNA-binding portion, ATF6-N (‘N’ for nuclear) which 
moves to the nucleus to activate gene expression (77, 78). This mechanism of proteolysis 
and activation is shared with the sterol response element binding proteins (SREBPs) 
where trafficking of inactive precursor to the Golgi apparatus occurs before proteolysis. 
However, the upstream initiating signals are different. Release of sterol repression 
activates trafficking of SREBPs, whereas an increase in unfolded proteins in the ER and 
release of BiP from luminal domain activates ATF6 (79, 80). This mode of translocation 
is accomplished by the presence of two independent and redundant Golgi localization 
sequences GLS1 and GLS2 in the ER-luminal domain of ATF6 (80). BiP binds to GLS1 
under normal conditions and sterically hinders GLS2 blocking its transport. Under ER 
stress conditions, unfolded proteins in the ER sequester BiP away from GLS1; GLS2 
becomes dominant and translocates ATF6 to the Golgi. There are also reports that ATF6 
is retained in the ER via its interaction with the lectin CRT (81). 
Cleaved active ATF6 binds the ER stress response elements (ERSE-I and -II) 
present in many UPR target genes like BiP, CHOP, ER degradation-enhancing α-
mannosidase-like protein 1 (EDEM1) and XBP1 in collaboration with the general 
transcription factor nuclear factor-Y (NF-Y), resulting in increased ER chaperone activity 
and degradation of misfolded proteins (44, 82). Induction of XBP1 mRNA by ATF6 is an 
important step in the ER stress signaling mechanism. Detection of spliced-XBP1 in ER 
stressed cells is always preceded by active nuclear form of ATF6α, thus emphasizing a 
close association of these two UPR effectors (31). The Mori lab proposed that the 
association of two transcriptional induction systems gives mammalian cells the capacity 
21 
 
 
to to cope with a wide range in amount of unfolded proteins. Unfolded proteins are 
refolded by ER chaperones activated by ATF6, constituting the ‘unidirectional’ ATF6-
mediated phase. However, if the ER stress is stronger and all unfolded proteins are not 
taken care of, ATF6-mediated XBP1 mRNA synthesis occurs. Active spliced-XBP1 
heterodimerizes with cleaved-ATF6 to induce ER chaperones as well as ERAD 
components through efficient binding of the ERSE element as compared to XBP1 
homodimers. This comprises a ‘bi-directional’ (refolding and degradation) ATF6-
mediated phase. This ability to transition between different phases of ER stress allows 
mammalian cells to properly utilize their full resources against ER stress (44, 83). 
In 2007, two groups independently generated mice with targeted deletions of the 
ATF6α gene (44, 84). ATF6α is not essential for embryonic and postnatal development. 
Even Atf6β-/- mice develop normally. However, ATF6α/β double knockout animals are 
embryonic lethal (44). Both groups showed the protective role of ATF6 during ER stress. 
As observed above, ATF6α is a positive regulator of ER chaperone expression and its 
deficiency reduced cell survival. Atf6α-/- mice did show significant attenuation of stress-
dependent induction of BiP and ERAD genes like EDEM and HRD1. ATF6α deficiency 
results in increased sensitivity to chronic stress in mice treated with ER stress inducer, 
tunicamycin (84). Interestingly, while ATF6α can activate CHOP under ER stress, it 
downregulates GADD34 that is responsible for dephosphorylation of the PERK target, 
eIF2α. Lower levels of GADD34 help sustain phosphorylation of eIF2α during chronic 
stress. Conversely, absence of ATF6α leads to the GADD34 synthesis and thus promotes 
the sensitivity to chronic stress by tunicamycin (84). Mori’s group also found a role for 
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PERK signaling in the activation of ATF6α. They found that both wild type and Perk-/- 
mouse embryonic fibroblasts (MEFs) showed cleavage of ATF6α to generate ATF6-N 
protein, but this activation was not sustained upon prolonged ER stress in Perk-/- cells in 
contrast to the wild-type cells. Accordingly, BiP induction was also attenuated. The 
authors propose that attenuation of ER chaperone induction by a deficiency of PERK 
signaling might be  due to blockage of ATF6α activation in the PERK-deficient cells 
(85). It was also observed that even though XBP1 expression was unaffected in both 
ATF6α and β- null cells, IRE1α-dependent XBP1 splicing is sustained in ATF6α null 
cells. This continued splicing leading to increased levels of active XBP1 may suggest a 
compensatory activation of IRE1 signaling in absence of ATF6α. Thus cross-talk of 
ATF6α occurs with both PERK and IRE1 pathways under stress conditions, thereby 
reinforcing redundancy in the UPR. IRE1 and PERK through their downstream effector, 
Wolfram syndrome 1 (WFS1) can negatively regulate ATF6α transcriptionally as well as 
mediate its degradation via the E3 ligase, HRD1. Mutations in WFS1 cause the 
autosomal recessive disorder, Wolfram syndrome; a rare form of juvenile diabetes 
characterized by a high level of ER stress and causing pancreatic β-cell death and 
neurodegeneration. The absence of WFS1 causes constitutive signaling of ATF6α which 
has a negative effect on β-cell survival (86, 87). 
DNA microarray analysis of Atf6α-/- cells showed 30 target genes for ATF6α, of 
which 18 were ER-related proteins, like chaperones, ERAD components and ER-resident 
proteins. The remaining 12 are yet to be categorized functionally. This suggests that 
ATF6 has a more limited role than XBP1 and may regulate ER quality control proteins 
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primarily (85). Previously, ATF6β was believed to have an antagonistic effect on ATF6α 
due to absence of an eight amino acid sequence, required for maximal transcriptional 
activity (88). However, Atf6β-/- mice do not show attenuation or enhancement of  stress-
dependent induction of ERSE-target genes, thereby disputing the suggestion that ATF6β 
has an antagonistic function (44). However embryonic lethality of double-knockout mice 
suggests that ATF6β might have a separate function from ATF6α. 
1.3. ER stress-induced apoptosis 
Even though IRE1, PERK and ATF6 can activate specific transcriptional and 
translational programs in response to an accumulation of unfolded proteins in the ER and 
maintain ER ‘homeostasis’, the load of misfolded or unfolded proteins can become too 
high for these transcriptional programs to handle. The ER tries to get rid of these 
misfolded proteins through ER associated degradation (ERAD) which forms a strict 
protein quality control mechanism. ER mannosidase I and a stress-inducible mannosidase 
homolog, EDEM are enzymes that can process misfolded glycoproteins by trimming 
mannose residues from N-linked glycans and thus monitor protein folding status in the 
ER (89). It is thought that the Sec61 translocon complex has a role in transport from the 
ER to the cytosol (90) where the proteins are degraded via the ubiquitin/proteasome 
pathway (9). Another complex containing Derlin-1 and p97, a cytosolic ATPase, helps 
retrotranslocation of major histocompatibility complex (MHC) class I molecules (91). 
However, even with all these mechanisms working, the ER might get overwhelmed. This 
brings us to the concept of ER stress-induced apoptosis. 
24 
 
 
IRE1 binds the TNF receptor-associated factor 2 (TRAF2) to activate the 
apoptosis signal-regulating kinase 1 (ASK1). This in turn activates the cJUN amino 
terminal kinase JNK pathway (27, 92). It has also been reported that the pro-apoptotic B-
cell leukemia/lymphoma 2 (BCL-2) family members BCL-2-associated X protein (BAX) 
and BCL-2 antagonist/killer (BAK) interact directly and activate IRE1α signaling (93). 
The IRE1α-ASK1-JNK pathway is responsible for cell death. JNK-mediated 
phosphorylation of cJUN is known to activate pro-apoptotic BIM (another BCL-2 family 
member) and inhibit the anti-apoptotic BCL-2 (94, 95). In fact, overexpression of BCL-2 
and BCL-XL (also anti-apoptotic) inhibit JNK activation and thus reduce cell death upon 
treatment with the ER stress inducer thapsigargin, which inhibits ER Ca2+-ATPase, 
blocking the entry of calcium into the ER (96). Release of Ca2+ from the ER upon ER 
stress is thought to be critically linked to life and death via activation of calpain, a 
protease that triggers the apoptotic caspase (97). Several BCL-2 family members as well 
as their interacting partners like Bax inhibitor I (BI-1) have been reported to modulate ER 
calcium homeostasis and control cell death induced by ER stress inducers like 
thapsigargin, tunicamycin, brefeldin-A (inhibitor of ER-golgi transport). Anti-apoptotic 
proteins like BCL-2, BCL-XL and BI-1 reduce basal Ca2+ levels in the ER (98, 99), 
whereas the pro-apoptotic BAX and BAK have an opposite effect (100). It is believed 
that if the ER has less calcium to release upon stress, then calcium levels in the cytosol 
will not rise to the levels required for activation of the deleterious apoptotic cascade. 
 Caspase-12, which is a cysteine protease involved in apoptosis, has also been 
reported to be a target of IRE1 signaling (97), though this protein is not found in humans 
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(101). Another major inducer of apoptosis is the bZIP transcription factor CHOP as 
mentioned earlier. CHOP promoter is bound by all three UPR transducers XBP1, ATF4 
and ATF6α. In addition to activating GADD34 which promotes protein biosynthesis by 
eIF2α dephosphorylation (74), CHOP downregulates BCL-2 thereby enhancing pro-
apoptotic BAX translocation from cytosol to mitochondria where it promotes release of 
cytochrome c from the mitochondrial lumen. Cytochrome c in turn activates cytosolic 
apoptotic protease activating factor (APAF1), which leads to activation of downstream 
caspase-9 and caspase-3 dependent cascade (102). CHOP can also activate the pro-
apoptotic BIM, a BH-3 protein (103). Recently a novel anti-apoptotic effector of the 
UPR, apoptosis antagonizing transcription factor, AATF has been characterized (104). 
AATF is regulated by PERK-mediated UPR signaling. It has been shown to 
transcriptionally activate the v-akt murine thymoma viral oncogene homolog 1 (AKT1) 
that protects cells from ER stress mediated cell death.  
Thus cytoprotective and cytotoxic pathways are thought to compete to determine 
whether the cell will survive ER stress. In 2007, Peter Walter’s group identified the role 
of IRE1 in the switching of cell fate in response to stress. They found that though ER 
stress activates all three UPR regulators, IRE1 activity falls off after 8 hrs, ATF6 activity 
lasts a bit longer but PERK activity was maintained even after 30 hrs at which point ER 
stress can kill cells. Chemical genetics assays revealed that if IRE1 activity is maintained 
in the face of persistent ER stress, cell survival was enhanced. This suggests that 
attenuation of IRE1 activity can be a trigger which allows cell death after UPR activation 
(105). However, this is dependent on ER stress conditions and the cell type used as IRE1 
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phosphorylation was found to be active under high glucose conditions for much longer 
time points in pancreatic β-cells (23, 106). A current model suggests the idea of a 
‘switch’ between ‘tolerable’ and ‘unresolvable’ ER stress. Tolerable ER stress entails 
expression of homeostatic regulators of the UPR, like XBP1, ATF4, ATF6α to mitigate 
the stress by proper folding or degradation of misfolded proteins. But persistent or 
excessive ER stress activates expression of apoptotic effectors like CHOP which 
outweigh the adaptive effectors of the UPR. This ‘switching’ activity of the UPR 
involves hyperactivation of UPR regulators, disruption of the negative feedback loops, 
and differential regulation of the prosurvival/homeostatic and the apoptotic players at 
both transcriptional and post-transcriptional levels (107). 
1.4. UPR in disease states 
The UPR maintains an important ER quality control system, perturbation of 
which as described above can result in cell death. This influence on the secretory 
pathway makes UPR signaling very important in several protein folding diseases. 
Endoplasmic reticulum stress has been associated with a number of diseases like 
neurodegeneration (Alzheimer’s disease, Parkinson’s disease), diabetes, cardiac disease, 
ischemic injury, bipolar disease, and cancer. 
1.4.1. Neurodegeneration and stroke 
PERK-eIF2α pathway has been found to be hyperactive in Alzheimer’s disease 
patients. The causative agent of this disease, amyloid-β peptide is produced by a complex 
proteolytic processing of the amyloid-β precursor protein (108). This processing involves 
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Presenilin-1 (PS1) protein whose mutant versions have been shown to block IRE1α, 
PERK and ATF6α, disrupt the ER calcium stores and may promote neuronal cell death 
via ER stress mediated apoptosis (109, 110). Parkinson’s disease involves hereditary 
mutations of a protein, α-synuclein, which is the principal component of Lewy bodies 
formed by aggregation of mutant protein, found in lesions in patients’ brain (111).  
Several other neurodegenerative diseases have been linked to ER stress due to inclusion 
body formation and protein aggregation. For example, amylotrophic lateral sclerosis 
which involves mutant aggregates of superoxide dismutase (SOD) in the ER (112), 
expanded polyglutamine (polyQ) diseases like Huntington’s disease and prion diseases 
like Creutzfeldt-Jakob disease, patients of which show increased levels of ER chaperones 
and accumulation of a misfolded and protease resistant form of prion protein PrP (113). 
Ischemic injury during stroke induces ER stress in neurons and activates the UPR. 
Activation of ASK1 and CHOP under these conditions leads to neuronal cell death (114). 
Genetic polymorphisms in the promoter of the XBP1 gene leading to lower expression 
levels have been linked to bipolar disorder (manic-depressive disease) in Japanese 
patients (115). Medications like valproate have been shown to increase expression of ER 
chaperones like BiP, GRP94 and Calreticulin, thus protecting against increased ER stress 
(116). 
1.4.2. Diabetes 
ER stress and a defective UPR have been implicated in diabetes. It was first 
discovered in a rare autosomal recessive form of juvenile diabetes, Wolcott-Rallison 
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syndrome. It is characterized by a mutation in PERK that is unable to mitigate ER stress 
caused by excessive insulin production in pancreatic β-cells after food intake. Excessive 
ER stress leads to β-cell death in these patients (56). ER-stress mediated cell death is 
involved in the pathogenesis of the autoimmune type 1A diabetes. Nitric oxide (NO), a 
mediator of inflammation induced by cytokines upregulated by ER stress in turn causes 
severe ER stress and induction of CHOP which leads to β-cell apoptosis (117, 118). 
These dying cells contain misfolded proteins which act as ‘neo-autoantigens’ that 
stimulate maturation of β-cell reactive T cells, which then mediate autoimmune 
destruction of remaining β-cells (119). Type 2 diabetes, which is characterized by insulin 
resistance in peripheral tissues, leads to hyper-production of insulin by the β-cell. This 
causes chronic activation of UPR, leading to β-cell dysfunction and death. One of the 
causes is chronic IRE1 activity that kills cells by JNK-mediated apoptosis (106). CHOP 
has also been shown to promote type 2 diabetes progression (120). XBP1 seems to have a 
protective effect against JNK activation (48). 
1.4.3. Heart disease  
ER stress is involved in heart diseases and the UPR markers have been found to 
be increased in myocardial ischemia, cardiac hypertrophy, heart failure and 
atherosclerosis. Expression of XBP1, GRP78 and PDI (protein disulfide isomerase) are 
increased during myocardial infarction (121, 122). GRP78 and GRP94 expression have 
been shown to reduce cardiomyocyte cell death under ischemic conditions (123, 124). ER 
stress-mediated activation of ASK1 and the pro-apoptotic PUMA, a member of the BCL-
29 
 
 
2 family, following aortic constriction as well as heart attacks have been shown to 
contribute toward cardiomyocyte cell death (125, 126). Transgenic mice expressing 
ATF6α show better recovery and cell cell death from infarction injury (127). ER stress is 
also induced by high cholesterol, oxidative phospholipids and homocysteine (a by-
product in high protein diets) in vascular cells and macrophages. These conditions can 
trigger apoptosis in endothelial cells via the IRE1-XBP1 signaling pathway thus causing 
atherosclerosis (121, 128).  
1.4.4. Autoimmune disorders 
Accumulation of unfolded proteins has also been implicated in autoimmune 
disorders like rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. 
Protein misfolding and defective modifications lead to creation of autoantigens in cells 
with a high degree of secretory activity, like pancreatic β-cells and plasma B-cells, as 
described earlier where the ERAD pathway is vulnerable. UPR signaling protects against 
these insults via the IRE1-XBP1 pathway, which activates ERAD and also helps in the 
maturation of plasma cells and dendritic cells, which are required for processing peptides 
for antigen presentation and secretion of cytokines (49, 129).  
1.5. UPR and Cancer 
The unfolded protein response has been reported to be activated in several types 
of cancer. Genetic variations in cancer cells cause these cells to inactivate their ability to 
destroy the damaged cells and hijack normal processes like cell cycle signaling, vascular 
development, nutrient metabolism and mechanisms of resistance to cell stress and 
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apoptosis. This enables the cells to survive, grow and divide without any limit and form 
malignant tumors. Poor vascularization (blood vessel formation or angiogenesis) of solid 
tumors leads to a stressful microenvironment characterized by low oxygen supply, 
nutrient deprivation and pH changes all of which are unsuitable for growth. These 
environmental conditions trigger a range of cellular processes aimed at the formation and 
attraction of new blood vessels to the tumor to help the tumor survive. Hypoxia signaling, 
which involves the activation of the pro-angiogenic hypoxia inducible factor-1α (HIF1α) 
is one of the major pathways activated in the tumors by low O2 levels. Increasing 
evidence shows that UPR is also activated by these conditions. 
Research on primary cells from breast tumors, hepatocellular carcinomas, 
esophageal adenocarcinomas and gastric tumors has revealed activation of XBP1, ATF6, 
CHOP, BiP, GRP94 and GRP170 among others (130-133). However, the role of the UPR 
in different forms of cancer has not yet been characterized fully. A recent study reveals 
that the UPR is downregulated in a mouse prostate cancer model (134). This suggests that 
the activity of UPR varies according to conditions and cell type and the interplay between 
its protective and destructive elements.  
Several studies have shown that BiP levels are increased in various cancer types 
including lung, colon and gastric cancers (135-137). Suppression of BiP in fibrosarcoma   
inhibited their ability to form tumors in mice (138) whereas in glioma cells it affected cell 
proliferation rate (139). In a BiP heterozygous mouse model, mammary tumor 
progression is significantly impaired as compared to wild-type animals mainly due to 
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reduction in the number of proliferating cells as well as an increase in number of 
apoptotic cells suggesting that BiP activation might protect cells from apoptosis (140). 
Versipelostatin, a compound which inhibits the rise in GRP78 levels as well as 
suppresses ATF4 and XBP1 levels has been shown to have selective cytotoxicity in 
glucose-deprived tumor cells and in mouse xenograft models (141).  
Some studies have shown that the IRE1-XBP1 signaling pathway is important for 
tumor growth under stress conditions. Research in Albert Koong’s lab showed that Xbp1-
/- and XBP1-knockdown cells did not form tumors in mice. However, in vitro growth 
rates and secretion of pro-angiogenic factor, VEGF, in response to hypoxia treatment 
were not diminished in these cells (142). XBP1 overexpression has been shown in 
various human cancers including breast cancer, liver cancer as well as neoplastic 
transformation of plasma cells and development of multiple myeloma in transgenic mice 
(143, 144). Other studies have shown that under ER stress IRE1 is required for activation 
of NF-κB, which has an important role in regulating cell survival and apoptosis (145). 
Also, VEGFA upregulation under conditions of hypoxia and glucose deprivation was 
impaired in tumor cells expressing a dominant-negative form of IRE1 (146) suggesting a 
role for IRE1 in tumor angiogenesis. When drugs which inhibit proteasome activity are 
added to cells already under ER stress, IRE1-dependent splicing of XBP1 mRNA is 
reduced and the apoptotic element of the UPR is activated resulting in cell death (47). 
Such drugs like Bortezomib, which can affect IRE1-dependent splicing, are already being 
used to treat multiple myeloma, thus underlining the importance of XBP1 in cancer 
development. 
32 
 
 
The PERK-eIF2α pathway also plays a role in protection from hypoxic stress in 
tumors. Studies in the Koumenis lab revealed that hypoxia rapidly increases 
phosphorylation of eIF2α through activation of PERK as well as increasing ATF4 and 
CHOP levels. In fact, transformed Perk-/- cells had lower survival rates under hypoxia 
(147). It should be noted that the ATF4 increase under hypoxia is dependent on PERK 
and not on the dominant HIF1 signaling pathway that is active under these conditions 
(148, 149). Tumors derived from cells expressing dominant-negative PERK which are 
defective in eIF2α phosphorylation were smaller in size and had higher levels of 
apoptosis (150). Also, angiogenesis was impaired in the tumors derived from Perk-/- 
transformed mouse embryonic fibroblasts (151). Similar to Perk-/- cells, Atf4-/- mouse 
embryonic fibroblasts (MEFs) were more sensitive to hypoxia that wild-type MEFs 
demonstrating higher levels of caspase-3, as well as failing to induce CHOP. As CHOP is 
pro-apoptotic, the increased sensitivity of Perk-/- and Atf4-/- cells to ER stress under 
hypoxia suggests that the PERK-ATF4 pro-survival pathway acts predominantly in tumor 
cells (147, 150, 152). 
All studies detailed above show that the UPR has a beneficial effect on survival of 
tumors under conditions of hypoxia and nutrient deprivation. However, some studies 
have shown that UPR might also contribute to dormancy or quiescence and may promote 
apoptosis. This might be due to the induction of the mitogen-activated protein kinase, 
p38, by the UPR that helps keep cells in a growth-arrested state (153). PERK can also 
inhibit cyclin D1 translation which leads to arrest of the cell cycle at the G1 stage and 
promotes dormancy (154). PERK signaling when activated independently of ER stress 
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showed impairment of cell proliferation and induction of apoptosis, which contrary to its 
cytoprotective role, can lead to tumor growth inhibition (155). However, it should be 
noted that inside the tumor, PERK signaling is coupled with other branches of UPR and 
hence the combined response might be different and cytoprotective for the tumors.  
The functional role of ATF6α has not been studied in detail. There are reports that 
increased ATF6 expression levels in primary tumors of colon cancer patients lead to 
higher chances of relapse (156). A recent study showed that ATF6α is an important 
survival factor for quiescent squamous carcinoma cells and its inactivation decreased 
rapamycin drug resistance. The authors show that p38 signaling through ATF6α mediates 
the pro-survival function in quiescent cancer cells (157). More detailed studies are 
needed to properly ascertain the role of ATF6α in cancer. 
1.6. Angiogenic signaling in cancer 
The dependence of tumor growth on blood vessel development or angiogenesis is 
an established fact in the field of cancer. Angiogenesis is absolutely important for the 
supply of oxygen, nutrients, growth factors and hormones, and the exchange of waste 
materials. This process involves recruitment of sprouting vessels from existing blood 
vessels and incorporation of endothelial progenitors into the growing tumor bed. This 
includes endothelial cell proliferation, migration, invasion and organization into 
functional tubular structures, maturation of vessels and finally vessel regression. 
Angiogenesis requires the balanced secretion of a large number of molecules like 
vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), 
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transforming growth factor-β (TGF-β), ephrins, angiopoietins and activation of their 
receptors and inhibitors like thrombospondins (158, 159). 
The VEGF family of proteins and receptors play a pivotal role in normal and 
pathological angiogenesis, not only in the context of tumor vascularization but also 
normal embryonic and placenta development. In both cases, growing cells rapidly 
outstrip the supply of nutrients leading to ER stress and activation of the unfolded protein 
response (160). Activation of the VEGF/VEGF-receptor (VEGFR) axis triggers multiple 
signaling networks resulting in cell survival, migration, mitogenesis, differentiation and 
permeability (161). The permeability induced by VEGF leads to deposition of proteins in 
the interstitium and facilitates angiogenesis. VEGF overexpression has been correlated 
with tumor progression in several cancers namely, colorectal, gastric, pancreatic, breast, 
prostate, lung cancer and melanoma (162-168). Because of its vast impact, VEGF 
research is of special importance in the field of cancer.  
1.6.1. VEGF ligand family 
The VEGF family consists of angiogenic and lymphangiogenic growth factors 
named as VEGFA, VEGFB, VEGFC, VEGFD, VEGFE and the phosphatidylinositol 
glycan class F or placenta growth factor (PIGF) -1 and -2 (169). VEGFA is the most 
common factor in this family and was originally identified as a vascular permeability-
inducing factor (VPF) secreted by tumor cells (170). VEGFA is a 45 kD homodimeric 
glycoprotein whose gene undergoes alternative splicing to yield mature isoforms of 121, 
165, 189 and 206 amino acids of which VEGF165 is the predominant isoform 
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overexpressed in a variety of human tumors (171). Other isoforms are distributed in a 
tissue-specific pattern and might have defined roles in vessel formation (172). VEGFC 
and D are required for lymphangiogenesis, VEGFE is a viral factor involved in 
angiogenesis, whereas PIGF is required for angiogenesis and in inflammation response 
(169). Targeted disruption of the VEGF gene in mice leads to embryonic lethality. 
Heterozygous deletion mutants are also embryonic lethal and are characterized by defects 
in intra and extra-embryonic blood vessel formation and impaired cardiac development at 
embryonic day 9.5. This phenotype is more pronounced in homozygous mutants (173). 
Thus VEGF is essential for mammalian development. VEGFA is also important for a 
number of normal angiogenic processes as well, including wound healing, ovulation, 
menstruation, maintenance of blood pressure and pregnancy (174, 175). VEGFA has also 
been linked to a number of pathological conditions other than cancer such as arthritis, 
psoriasis, macular degeneration and diabetic retinopathy (169). 
VEGFA reprograms the endothelial cell gene expression to favor the growth, 
proliferation and survival of the vasculature. These proteins include blood clotting 
factors, fibrinolytic proteins like urokinase, tissue-type plasminogen activator, matrix 
metalloproteases, type I plasminogen activator inhibitor, GLUT-1 glucose transporter, 
nitric oxide synthase, a variety of mitogens, several anti-apoptotic molecules (BCL-2, 
survivin, XIAP) and adhesion molecules (E-selectin, ICAM-1, VCAM) (169, 176). 
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1.6.2. VEGF receptor signaling 
VEGF ligands mediate their angiogenic effects via different receptors leading to 
dimerization and signal transduction. There are three primary receptors. VEGFR-1 and 
VEGFR-2 are associated with angiogenesis, VEGFR-3 has a role in lymphangiogenesis. 
There are also two co-receptors, Neuropilin-1 and -2 (177, 178).These co-receptors 
increase the binding efficiency of various VEGF ligands to their primary receptors. Most 
VEGF receptors are found on the surface of endothelial cells, but they may also be 
expressed by tumors (179). VEGFR-1 binds VEGFA, VEGFB and PIGF and is normally 
associated with embryogenesis and not in pathogenic angiogenesis (177). VEGFR-2 
mediates most downstream VEGFA signaling like endothelial cell proliferation, invasion, 
migration and survival by phosphorylation of downstream proteins including protein 
kinase C, phospholipase C-γ, phosphatidylinositol 3-kinase (PI3K), and activation of the 
survival kinase, v-akt murine thymoma viral oncogene homolog (AKT) (180). 
Mammalian target of rapamycin (mTOR) and endothelial nitric oxide synthase contribute 
to VEGFA/VEGFR-2 mediated microvascular permeability (181, 182). VEGFR-3 
mediates lymphangiogenesis and is found only in lymphatic endothelial cells in adults 
(183). 
1.6.3. VEGFA regulation 
VEGFA synthesis and secretion is triggered by a number of genetic and 
environmental factors. These include hypoxia, oncogenes, tumor suppressor genes, 
growth factors and cytokines. Hypoxia activates a transcription factor known as hypoxia 
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inducible factor (HIF) to regulate VEGFA. Both tumor cells as well as developing 
embryos experience hypoxic environments. Binding of HIF to the promoter of VEGFA is 
a key step in determining VEGFA activity (184). Hypoxic response genes like VEGF and 
HIF-1α have unusually long 5’ UTRs with extensive secondary structures that enables 
them to be efficiently translated under stress conditions (185). HIF activity increases 
progressively with decreasing O2 gradient from 5% to 0.1% which is close to anoxia. It 
belongs to a family of basic-helix-loop-helix (bHLH) proteins and is a heterodimer of a 
constitutively expressed stable HIF-1β subunit and one of three oxygen-regulated HIF-α 
subunits (HIF-1α, -2α or -3α). HIF binds to a motif known as hypoxia-response-element 
(HREs) with a minimal core sequence 5`-RCGTG-3` which is present in its downstream 
target genes one of which is VEGF (186, 187). HIF does not directly sense changes in O2. 
Two types of oxygen sensors namely prolyl hydroxylase domain (PHD) protein and 
factor inhibiting HIF-1 (FIH) control HIF activity. Hydroxylation takes place at the 
oxygen dependent degradation domain (ODDD) and carboxy-terminal transcriptional 
activation domain (C-TAD) of HIF respectively. The first modification promotes 
interaction of HIF with tumor suppressor von Hippel-Lindau (VHL) protein which is a 
component of the E3-ubiquitin ligase complex which marks the protein for 
degradation(188, 189). HIF-1α protein has one of the shortest half-lives of any protein, 
less than 5 minutes under normoxic (21% O2) conditions (189). The second modification 
blocks transcriptional co-activators p300 and its paralog CBP, thus inactivating HIF-1α 
(189). However, when oxygen is limiting these oxygen sensors have lower affinity and 
HIF-1α is stabilized. 
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Oncogenes that increase VEGF production include c-Src, BCR-ABL, mutant H 
and K-Ras. Loss of function in tumor suppressors, like p53 and VHL, also lead to VEGF 
expression (189). Growth factors and cytokines like the epidermal growth factor receptor 
(EGFR), insulin-like growth factor-1 receptor (IGF-1R), platelet-derived growth factor 
(PDGF) and cyclooxygenase (COX-2) are all involved in VEGF regulation (176, 190). 
VEGF is not only controlled at the transcriptional level, but post-transcriptional 
regulation of VEGF has also been reported. The VEGF mRNA is labile under normal 
oxygen tension. It is stabilized by hypoxia-mediated binding of AU-rich elements (AREs) 
(that are responsible for targeting the mRNA for degradation) in the 3’-untranslated 
region (UTR) of VEGF mRNA by the RNA-binding protein, HuR (191). The presence of 
internal ribosome entry site (IRES) sequences in the 5’-non-coding region of VEGFA 
mRNA  also help in cap-independent translational initiation of VEGFA under both 
hypoxia and nutrient deprivation (192). VEGF mRNA is also stabilized by activation of 
the stress-activated protein kinase, p38, (193) which can be upregulated by the UPR. 
Hence, to date, HIF-1 dependent transcriptional regulation of VEGFA has been 
studied in detail. However, emerging studies indicate that HIF-1 independent pathways 
might also have a direct role in regulation of VEGFA. One of them is the UPR pathway. 
1.7. VEGFA regulation and UPR signaling 
Evidence for the role of other environmental factors in VEGFA upregulation are 
growing in number. Hypoxia is almost always accompanied by low nutrient availability 
and low pH conditions. VEGF synthesis and secretion is absolutely essential for tumors 
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as well as the developing embryo which experience these extreme conditions. Since 
VEGF is a secretory protein produced in large amounts in tumors as well as endothelial 
or vascular vessels, ER stress occurs and leads to activation of the UPR. There is already 
some evidence that the UPR is involved in VEGFA upregulation. 
1.7.1. Summary of previous findings 
The mechanism of UPR signaling pathway-mediated VEGF expression and 
secretion has not been studied in detail. As discussed previously, IRE1 has been shown to 
be required for VEGF expression  in tumor cells under ischemic conditions (146). A 
recent study has revealed that VEGF dysfunction in the placenta is the cause of 
embryonic lethality of Ire1α-/- mice (194).  
Normal embryonic development is characterized by a rapid growth of blood 
vessels along with decidualization, development of vascular membranes, organogenesis 
and placenta formation. VEGF-heterozygous mutants are embryonic lethal at d10.5. In 
situ hybridization of VEGF mRNA in sections of rat embryos revealed maximum signal 
in the trophoblast giant cells, labyrinth and vascular membranes of the placenta and the 
mesometrium at the early and mid-gestational stage. In contrast, the embryo had lower 
levels of mRNA than the placenta until later in development (195). This suggests that the 
early development of the vascular system is dependent on proper expression of VEGF 
and thus it may have a role in the lethal phenotype of Ire1α-/- mice. 
Also studies from the Koong laboratory revealed that XBP1 is essential for tumor 
growth and angiogenesis; however, XBP1 deficiency does not show any difference in 
40 
 
 
VEGF expression in some human fibrosarcoma and human pancreatic cancer cell lines 
(142, 196). Microarray analysis of Perk-/- cells showed an attenuation in VEGFA 
expression under hypoxic conditions as compared to wild-type MEFs (151). However, 
secreted VEGF levels are not statistically different between wild-type cells and cells with 
a non-phosphorylatable ‘knock-in’ mutation of eIF2α (S51A) under extreme hypoxia (≤ 
0.02%) (150). 
 As mentioned earlier, ATF4, which is downstream of the PERK-eIF2α pathway 
of UPR is also downstream of other eIF2α kinases. ATF4 has been found to regulate 
VEGFA expression under oxidative stress conditions, which can activate the upstream 
eIF2α kinase, HRI. Studies on the human VEGFA gene showed that ATF4 binds a DNA 
element at +1767 bp relative to VEGF transcription start site in the human retinal 
pigmented epithelial cell line ARPE-19 (197).  Also, homocysteine, a homolog of the 
amino acid cysteine which has been associated with age-related macular degeneration 
(AMD), has been shown to upregulate VEGF in ARPE-19 cells (198). However, the 
exact mechanism of activation has not been elucidated yet under ER stress conditions. 
ATF6α has not yet been shown to have a direct effect on VEGF expression. 
1.7.2. Significance of studying the mechanism of ER stress-mediated VEGFA 
upregulation 
The contribution of the unfolded protein response pathway towards VEGFA 
expression has not been studied in detail. Studies mentioned above have just observed 
what happens in the absence of one or two players and their effect on VEGF expression 
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and blood vessel development or angiogenesis. But they point to one fact, that the UPR is 
definitely a significant player in VEGFA mediated angiogenesis. Because angiogenesis 
regulation is of profound importance in diseases like cancer as well as normal 
development, it becomes imperative to study all pathways that have a role in it. 
Determining how IRE1, PERK and ATF6 regulate VEGFA expression will help to 
establish direct assays to target these pathways for novel therapeutics against 
angiogenesis in cancer. Also, determining how and why the placenta lethal phenotype 
occurs in Ire1α-/- embryos will lead us to elucidate the crucial role of IRE1 in normal 
mammalian development. 
1.7.3. Summary of thesis research: Transcriptional regulation of VEGFA expression 
by the UPR under ER stress 
In this thesis, we asked the primary question, what is the role of the unfolded 
protein response in regulation of VEGFA?  We have been able to show exactly how the 
three upstream branches of the UPR are able to regulate VEGFA expression by 
interacting with the VEGFA gene.  IRE1α regulates VEGFA transcriptionally through its 
downstream effector, XBP1 which binds the VEGFA promoter under ER stress. PERK 
regulates VEGFA through its downstream effector, ATF4, which binds the first intron of 
VEGFA under ER stress. Finally, ATF6α cleavage occurs under ER stress, and cleaved 
ATF6α is able to regulate VEGFA by binding its promoter. We also show that the UPR is 
able to not only regulate VEGFA expression, but also can affect protein synthesis and 
secretion of VEGF. Our results also show that all three regulators are required for 
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VEGFA regulation under ER stress conditions. Downregulation of any one of them 
causes attenuation of VEGFA expression. 
Preliminary work in our lab showed that Ire1-/- animals were embryonic lethal and 
the labyrinthine trophoblast region of the placenta was malformed. This suggests that the 
UPR regulator, IRE1 might play a major role in vascular development during early 
development. Because VEGF heterozygous mutants are embryonic lethal at d10.5, and 
have high expression in the labyrinth of placenta, this suggests that the early development 
of the vascular system is dependent on proper expression of VEGF which is again 
dependent on the UPR. We found that VEGFA expression is indeed controlled by IRE1α 
signaling in labyrinthine trophoblast cell line, thereby underlining IRE1α’s essential role 
in normal mammalian development. 
Taken together, work in this thesis strongly suggests that the UPR plays a 
significant role in VEGFA expression and thus has a profound effect on angiogenesis. 
This thesis establishes the mechanism of VEGFA regulation by the UPR regulators and 
lays the groundwork for targeting the upstream components of the UPR pathway with 
novel therapeutics which can specifically block VEGFA expression to serve along with 
existing anti-angiogenic agents used in treatment of solid tumors. 
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CHAPTER II:  IRE1α AND ΑΤF6α BOTH HAVE A ROLE IN 
TRANSCRIPTIONAL REGULATION OF VEGFA EXPRESSION IN 
MAMMALIAN CELLS 
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Summary 
The endoplasmic reticulum is the primary organelle within the cell which is 
responsible for the proper folding of secretory proteins to their final active state required 
for the normal homeostatic functions in the body, like cell growth and development, 
metabolism, response to environmental stress and survival. One of the crucial events in 
mammalian development is the formation of blood vessels or angiogenesis and is 
associated with restrictive environmental conditions like nutrient deprivation and 
hypoxia. VEGFA, a crucial secretory protein that is essential for angiogenesis, helps in 
proper distribution of growth factors and nutrients required for growth and survival of 
cells and thus maintains homeostasis. Stressful environmental conditions can increase the 
load of unfolded polypeptides in the ER to exceed its capacity to fold them, thus causing 
‘ER stress’. This causes activation of an intracellular adaptive response known as 
unfolded protein response (UPR). IRE1α and ATF6α are UPR regulators that respond to 
ER stress by activating downstream transcription factors that help to alleviate the stress 
by activating genes required for efficient folding as well as disposal of unfolded proteins 
and thus maintaining homeostasis in the ER. VEGFA shows elevated expression levels 
under harsh environmental conditions like nutrient deprivation and hypoxia.  Here we 
show that VEGFA is a target of the UPR and that IRE1α and ATF6α have a critical role 
in the normal expression of VEGFA under ER stress conditions. IRE1α upon activation 
by ER stress can uniquely splice XBP1 mRNA to yield a potent transcription factor, 
XBP1s, which binds the VEGFA promoter to upregulate its expression. ATF6α is 
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cleaved under ER stress and its cleaved cytoplasmic domain, ATF6α-N, acts as another 
potent transcription factor which binds the VEGFA promoter and activates its expression. 
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Introduction 
Inositol requiring-1 (IRE1) is an approximately 100 kD type I transmembrane 
protein that has both a serine/threonine kinase domain and an endoribonuclease domain. 
IRE1 is a primary ER stress sensor and the most evolutionarily conserved branch of the 
unfolded protein response (UPR) among all eukaryotes. It was first identified in yeast as 
an unfolded protein sensor in the ER. Mammalian IRE1 gene has two forms IRE1α and 
IRE1β. IRE1α is ubiquitous whereas IRE1β is expressed in intestinal epithelial cells (24-
26). IRE1α is essential for normal development as mutants are embryonic lethal by 
E12.5, whereas IRE1β deletion does not cause any significant defects (26, 27). The N-
terminal ER luminal domain is associated with the chaperone BiP (GRP78) under normal 
conditions. Dissociation of  BiP in response to accumulation of unfolded proteins under 
ER stress conditions  causes dimerization and activation of mammalian IRE1(28-30). The 
C-terminal domain of IRE1 has two enzymatic activities, a kinase and an 
endoribonuclease. Upon oligomerization, the kinase domains come in contact and trans-
autophosphorylate each other. This autophosphorylation activates the RNase  domain to 
cleave a specific 26-nucleotide intron from the XBP1 mRNA which encodes a 
transcription factor (31, 32). Ligation of cleaved XBP1 mRNA shifts the open-reading 
frame resulting in the conversion of  the 267 amino acid unspliced XBP1 protein to a 371 
amino acid potent transcription factor called XBP1s where ‘s’ indicates spliced form (31-
33). Spliced XBP1 has a role in upregulation of a broad spectrum of UPR genes which 
are involved in protein folding, entry into the ER, ER-associated degradation (ERAD) 
and protein quality control (34, 35).  
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IRE1 also binds to adaptor protein TRAF2 under strong and irreversible ER stress 
and can then activate apoptosis through the ASK1-JNK pathway (27). Another interesting 
role of IRE1 recently identified is the degradation of a selective group of mRNAs, which  
encode proteins that are difficult to fold in the ER (39). The mRNA degradation activity 
required Ire1α dimerization and autophosphorylation by ER stress whereas XBP1 
splicing activity can be restored without kinase activation. It has been proposed that IRE1 
can affect cell fate  by acting as a switch by altering its kinase activity in order to either 
favor XBP1 splicing to maintain homeostasis or cause mRNA decay which can lead to 
apoptosis (38). One of the mRNAs that are degraded by IRE1 encodes the secretory 
protein, insulin (37).  
Another major regulator of the unfolded protein response pathway comprises the 
type II ER transmembrane protein, activating transcription factor-6 (ATF6) that encodes 
a basic leucine zipper (bZIP) transcription factor in its cytoplasmic domain. Mammalian 
ATF6 consists of two homologous proteins, ATF6α and ATF6β. The luminal domain of 
ATF6 binds BiP, similar to IRE1α. When BiP is titrated away by unfolded proteins in the 
ER because of ER stress, ATF6 translocates to the Golgi where its cytosolic domain gets 
cleaved to yield a potent transcription factor, ATF6-N (‘N’ for nuclear) which moves to 
the nucleus to activate gene expression (77, 78). Cleaved active ATF6 binds the ER stress 
response elements (ERSE-I and -II) present in many UPR target genes like BiP, CHOP, 
EDEM and XBP1 in collaboration with the general transcription factor nuclear factor-Y 
(NF-Y) resulting in increased ER chaperone activity and degradation of misfolded 
proteins (44, 82).  
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ATF6α is not essential for embryonic and postnatal development. Even Atf6β-/- 
mice develop normally. However, ATF6α/β double knockout animals are embryonic 
lethal (44). Atf6α-/- mice show significant attenuation of stress-dependent induction of BiP 
and ERAD genes like EDEM and HRD1. ATF6α deficiency results in increased 
sensitivity to chronic stress in mice treated with ER stress inducer, tunicamycin (84). 
There is evidence of cross-talk between ATF6α and both the PERK and IRE1 pathways 
under stress conditions thereby reinforcing redundancy in the UPR. While ATF6α can 
activate CHOP under ER stress, it downregulates GADD34 which is responsible for 
dephosphorylation of the PERK target, eIF2α thus delaying the recovery of protein 
synthesis (84). PERK is required to maintain ATF6α activation for induction of ER 
chaperones under ER stress (85). It was also observed that IRE1α-dependent XBP1 
splicing compensates for ATF6α inactivation by increasing spliced XBP1 output. IRE1 
and PERK through their downstream effector, Wolfram syndrome 1(WFS1) can 
negatively regulate ATF6α transcriptionally as well as mediate its degradation via the E3 
ligase, HRD1-mediated ubiquitin-proteasome pathway (86, 87). 
DNA microarray analysis of Atf6α-/- cells showed 30 target genes for ATF6α, of 
which 18 were ER-related proteins like chaperones, ERAD components and ER-resident 
proteins. The remaining 12 are yet to be categorized functionally. ATF6 is primarily 
involved in ER quality control process (85).  
Spliced XBP1 (XBP1s) signaling represents the homeostatic survival arm of IRE1 
activity. XBP1s binds the unfolded protein response element (UPRE) with a highly 
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conserved ACGT core (40, 41) or the CCACG box which is part of the composite ER 
stress response element (ERSE) in the promoters of its target genes which include XBP1 
itself (42). It is expressed significantly in secretory cells which have an extensive network 
of ER to synthesize and fold secreted proteins like pancreatic β-cells, antibody secreting 
plasma cells, liver hepatocytes etc. Genome-wide profiling revealed that XBP1 has roles 
in cell differentiation, signaling and DNA damage repair pathways in a cell and tissue 
type-specific manner (42). XBP1s regulates the expansion of the secretory pathway by 
controlling ER/Golgi biogenesis and phospholipid biosynthesis (35, 43). XBP1s also 
heterodimerizes with ATF6α to induce ER-associated degradation of misfolded proteins, 
thereby providing robustness in its response to ER stress (44). Interestingly, the unspliced 
form of XBP1 protein, XBP1u, has been shown form a complex with XBP1s and directs 
it to the proteasome for degradation,  thus acting as a negative feedback regulator of 
XBP1s (45).  
Xbp1-/- mice are embryonic lethal and suffer from severe liver hypoplasia (13). 
Specific deletion in immune cells blocks terminal differentiation of B cells into antibody 
secreting plasma cells (49). Ire1α-/- animals are also embryonic lethal and preliminary 
observations in our lab found a defect in formation of the labyrinth in their developing 
placenta. This observation made us look for the role of IRE1α in the developing placenta, 
which makes it essential for survival of the embryo. 
The placenta is the first organ to form during mammalian embryogenesis. It 
provides an interface between the fetal and maternal environments and facilitates the 
50 
 
 
exchange of gases, nutrients and waste products. The placenta also acts as a source of 
hormones and growth factors, and is involved in the immune protection of the fetus 
making it essential for survival of the embryo. In mice, the placenta is formed by fusion 
of the embryo-derived allantois (forms the umbilical cord) and the extra-embryonic 
chorion that derives from the polar trophectoderm (trophoblast progenitor formed from 
the primary differentiation of the blastula) overlying the inner cell mass (forms embryo) 
of the blastula. Chorioallantoic attachment at day 8.5, accompanied by  increased 
transcriptional activity, causes the chorionic trophoblast to differentiate into various 
layers of labyrinthine trophoblast cells that undergo extensive villus branching to form 
the complete labyrinth by E10.5 (199). The formation of this layer is critical for 
integration and exchange between fetal and maternal blood vessels (Figure 2.1) (200, 
201).  It has been reported that hypoxia and nutrient deprivation, which have been shown 
to activate both IRE1α and PERK in this study, are involved in various stages of 
placental development, one of them being trophoblast differentiation (201-203). The 
labyrinthine trophoblast is characterized by an extensive network of blood vessels that is 
crucial to many physiological and pathological processes including development of 
labyrinthine trophoblast cells in the placenta (173, 199, 200). 
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Figure 2.1. Schematic of Mouse placenta. This cartoon shows the structure of embryonic 
day 10.5 mouse placenta (204). 
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One of the major regulators of angiogenesis is vascular endothelial growth factor, 
VEGFA. VEGFA is a secretory protein that reprograms the endothelial cell gene 
expression to favor the growth, proliferation and survival of the vasculature. It is the most 
common of the family of VEGF proteins. The VEGFA gene undergoes alternate splicing 
to yield several mature isoforms of which VEGF165 is the predominant isoform 
overexpressed in a variety of human tumors (171). Targeted disruption of the VEGF gene 
in mice leads to embryonic lethality. Heterozygous deletion mutants are lethal and are 
characterized by defects in intra and extra-embryonic blood vessel formation and 
impaired cardiac development at embryonic day 9.5. This phenotype is more pronounced 
in homozygous mutants (173). Thus VEGF is essential for mammalian development. 
Preliminary experiments in our lab as well as another group show that VEGFA is 
upregulated under ER stress and that the IRE1 pathway might be responsible for 
upregulation of VEGFA upregulation under ER stress (146). We found that depletion of 
IRE1 causes attenuation of VEGFA mRNA levels in ER stressed cells. A very recent 
study has revealed that VEGF dysfunction in the placenta may be the cause of embryonic 
lethality of Ire1-/- mice (194). However the mechanism of this regulation is unknown. 
The presence of a long 5’UTR and internal ribosomal entry site (IRES) puts 
VEGF under the control of various transcriptional regulators which respond to different 
kinds of stress (192). One of the major regulators of VEGFA is the hypoxia inducible 
factor 1-α (HIF-1α). Tumor cells, as well as the developing embryo, experience hypoxic 
environment. Binding of HIF1α to the promoter of VEGFA is a key step in determining 
VEGFA activity (184). Hence we wondered whether HIF1α was the link between IRE1 
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and VEGFA upregulation under ER stress in the placenta. Our experiments in a placenta 
cell line show that the hypoxia regulatory pathway is not involved in upregulation of 
VEGFA under ER stress. This result emphasizes that the UPR must be playing a crucial 
role in VEGFA regulation through IRE1α activity, along with hypoxia in the placenta. 
VEGF mRNA is also stabilized by the induction of stress-activated protein 
kinases (SAPKs) like JNK and p38 (193). As IRE1α is involved in activation of the JNK 
signaling pathway under extreme ER stress, we investigated whether IRE1α has a role in 
stabilizing VEGF mRNA under ER stress  We found that IRE1α is not involved in 
VEGFA mRNA stabilization, indicating that IRE1α regulates VEGFA transcriptionally. 
Previous studies had shown that XBP1 is important for tumor growth under stress 
conditions. XBP1 overexpression was found in various human cancers, including breast 
cancer and liver cancer. It is involved in neoplastic transformation of plasma cells and the 
development of multiple myeloma in transgenic mice (143, 144). Because the main 
downstream effector of IRE1 under ER stress is spliced XBP1, we investigated whether 
XBP1 regulates VEGFA. We found that XBP1s is able to activate the VEGFA promoter.  
Our results revealed that XBP1 binds and activates VEGFA promoter under ER stress. 
Spliced XBP1 can also rescue VEGFA levels in Ire1α-/- mouse embryonic fibroblasts 
(MEFs). Our experiments also revealed that IRE1α is required for normal VEGFA 
protein synthesis and secretion in cells under ER stress. Thus we concluded that the 
IRE1-XBP1 pathway regulates the promoter of VEGFA under ER stress. 
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ATF6α has not yet been shown to have a direct effect on VEGFA expression. 
Induction of XBP1 mRNA by ATF6 is an important step in the ER stress signaling 
mechanism. It has already been shown that active spliced-XBP1 can  heterodimerize with 
cleaved-ATF6 (ATF6-N) to induce ER chaperones as well as ERAD components through 
more efficient binding of the ERSE as compared to XBP1 homodimers (44, 83). Hence 
we asked the question whether ATF6α can also regulate VEGFA expression. We found 
that overexpression of cleaved ATF6α-N activates the VEGFA promoter similar to 
XBP1s. We also found that siRNA-mediated knockdown of ATF6α caused attenuation of 
VEGFA under ER stress conditions. Because XBP1s binds the VEGFA promoter, we 
hypothesized that cleaved ATF6α-N might also regulate VEGFA by binding the promoter 
as it is known to form a heterodimer with XBP1s. Indeed, we found that cleaved ATF6α-
N binds the VEGFA promoter.  
These findings helped us characterize IRE1α and ATF6α-mediated regulation of 
VEGFA promoter. Our studies provide a valuable insight into how angiogenesis can be 
regulated by the unfolded protein response through its influence on VEGFA expression. 
These findings not only help to explain the Ire1α-/- lethal phenotype but also open up a 
promising window for modulation of angiogenesis by inhibiting IRE1α-XBP1 and the 
ATF6α signaling pathway. 
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Materials and Methods 
Cell culture 
Hepatocellular carcinoma cell line, HepG2, and human prostate cancer cell line, 
PC3, were obtained from ATCC. HepG2 was maintained in MEM with supplements 
according to ATCC cell culture instructions. PC3 was maintained in DMEM with 10% 
FBS. Rat insulinoma cells, INS-1 832/13, were a gift from Dr. Christopher Newgard 
(Duke University Medical Center) and cultured in RPMI 1640 supplemented with 10% 
FBS. Wild-type (149) and Ire1α-/- mouse embryonic fibroblasts were gifts from Dr. 
David Ron (New York University School of Medicine) and maintained in DMEM 10% 
FBS.  Mouse labyrinthine trophoblast SM10 cells were a gift from Dr. Joan Hunt 
(University of Kansas) and maintained in RPMI 1640 supplemented with 2 mM 
glutamine, 1%  sodium pyruvate, 5x10-5 M 2-mercaptoethanol and 10% FBS. Human 
embryonic kidney 293T cells and mouse neuro2a cells were obtained from ATCC and 
maintained in DMEM with 10% FBS.  
Plasmids 
Mouse ATF4, mouse XBP1-processed, human IRE1α and human IRE1αKA 
(K599A) dominant-negative kinase mutant plasmids were provided by Dr. David Ron 
(New York University School of Medicine). Mouse ATF5 plasmid was a gift from Dr. 
Michael Green (University of Massachusetts Medical School). Cleaved processed 
ATF6(Δ373) plasmid was provided by Dr. R. Prywes (Columbia University). 
56 
 
 
Lentivirus system 
Lentivirus expressing human IRE1α, human IRE1αKA and GFP were generated 
by subcloning these fragments into a lentiviral expression plasmid, pLenti-CMV/TO (Dr. 
Eric Campeau at the University of Massachusetts Medical School). Lentivirus was 
produced in HEK293T cells by transfection using Lipofectamine2000 (Invitrogen 
Carlsbad, CA). Lentiviral supernatant was collected 48 h after transfection, and stored at -
80 °C. Lentiviral vectors were based on modified Gateway technology (Invitrogen 
Carlsbad, CA) (205). Ire1α-/- MEFs were infected with human IRE1α lentiviral 
supernatant and selected with puromycin 2 μg/ml to generate a stable cell line. SM10 
cells were infected with human IRE1αKA and control GFP lentivirus and selected with 
puromycin 1 μg/ml to generate stable cell lines. 
siRNA and plasmid  transfection 
Small interfering RNA (siRNA) was transfected using the Cell Line 
NucleofectorTM Kit V and the Nucleofector Device (Amaxa Biosystems, Gaithersburg, 
MD) into HepG2 cells using Nucleofector program T-028. Human HIF1-α smart pool 
siRNA was obtained from Dharmacon, (Lafayette, CO). SiRNAs directed against human 
IRE1α and human XBP1 were synthesized by IDT (Coralville, IA): for human IRE1: 
AGACAGAGGCCAAGAGCAA; for human XBP1: GGTATTGACTCTTCAGATT; for 
human ATF6α: GAACAGGATTCCAGGAGAA. Cells were incubated in media 
overnight after siRNA transfection, and then put under ER stress. Mouse XBP1-
processed plasmid was transfected into Ire1α-/- MEFs using the Cell Line NucleofectorTM 
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Kit MEF2 and the Nucleofector device (Amaxa Biosystems, Gaitherburg, MD) using 
Nucleofector program T-020. 
Western blotting 
Lysates were extracted using NE-PER® Nuclear and Cytoplasmic Extraction 
Reagents (Pierce Biotechnology, Rockford, IL) supplemented with protease inhibitors. 
Lysates were normalized for total protein (20 μg per lane) for nuclear extracts and total 
protein (50 μg per lane) for cytoplasmic extracts and separated using 4%-20% linear 
gradient SDS-PAGE (BioRad, Hercules, CA) and transferred to a nitrocellulose 
membrane. After blocking for 1h at room temperature in TBS-T with 5% nonfat dry milk, 
membranes were incubated at 4°C overnight in TBS-T with 5% nonfat dry milk 
containing a 1:1000 dilution of antibody and washed 3 times with TBS-T. The 
membranes were then incubated for 1 h at room temperature in TBS-T with 5% nonfat 
dry milk containing a 1:3000 dilution of secondary IgG antibody (Cell Signaling, 
Danvers, MA) coupled to horseradish peroxidase (HRP), followed by washing 3 times 
with TBS-T. Immunoreactive bands were visualized by incubation with enhanced 
chemiluminescence (ECL) (Pierce, Rockford IL) and exposed to x-ray film.  Anti-XBP1, 
anti- CHOP and anti-actin antibodies were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-IRE1α antibody was obtained from Cell Signaling (Danvers, 
MA). Anti-HIF1α, anti-phospho IRE1 antibodies was obtained from Novus Biologicals 
(Littleton, CO). 
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Quantitative polymerase chain reaction 
 Total RNA was isolated from the cells by using the RNeasy Mini Kit (Qiagen, 
Valencia, CA). 1 μg of total RNA from cells was reverse transcribed with Oligo-dT 
primer (Promega, Madison, WI). For the thermal cycle reaction, the iQ5 system (BioRad, 
Hercules, CA) was used at 95°C for 10 min, then 40 cycles at 95°C for 10 sec, and at 
55°C for 30 sec. The relative amount for each transcript was calculated by a standard 
curve of cycle thresholds for serial dilutions of cDNA sample and normalized to the 
amount of the house-keeping beta-actin levels.  The polymerase chain reaction (PCR) 
was performed in triplicate for each sample; all experiments were repeated three times.  
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) was used 
for the quantitative PCR. PCR primer sequences are listed in following table: 
Species Gene Forward Sequence 5'-3' Reverse Sequence 5'-3' 
Mouse Actin GCAAGTGCTTCTAGGCGGAC AAGAAAGGGTGTAAAACGCAGC 
Mouse  Vegfa TGAAGCCCTGGAGTGCGT AGGTTTGATCCGCATGATCTG 
Mouse Spl. Xbp1 CTGAGTCCGAATCAGGTGCAG GTC CATGGGAAGATGTTCTGG 
Mouse Chop CCACCACACCTGAAAGCAGAA AGGTGAAAGGCAGGGACTCA 
Mouse Hif1α GATTCGCCATGGAGGGC TTCGACGTTCAGAACTCATCTTTT 
Rat Actin GCAAATGCTTCTAGGCGGAC AAGAAAGGGTGTAAAACGCAGC 
Rat BiP TGGGTACATTTGATCTGACTGGA CTCAAAGGTGACTTCAATCTGGG 
Rat Vegfa CAAGCCGTCCTGTGTGCC TCCAGGGCTTCATCATTGC 
Human  GAPDH TGTTCGACAGTCAGCCGC GGTGTCTGAGCGATGTGGC 
Human HIF1α AGGAGGATCACCCTCTTCGT TCTCCTCAGGTGGCTTGTC 
Human  VEGFA CCTTGCTGCTCTACCTCCAC ATGATTCTGCCCTCCTCCTT 
Human  IRE1a GGCCTGGTCACCACAATTAGA TTTGGGAAGCCTGGTCTCC 
Human  Spl. XBP1 CTGAGTCCGAATCAGGTGCAG ATCCATGGGGAGATGTTCTGG 
Human  BiP TGTTCAACCAATTATCAGCAAACTC TTCTGCTGTATCCTCTTCACCAGT 
Human EDEM CAAGTGTGGGTACGCCACG AAAGAAGCTCTCCATCCGGTC 
Human ATF6 TTGGGACATCAACAACCAAA ACCGAGGAGACGAGACTGA 
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mRNA stability assay 
Cellular mRNA transcription was attenuated by treating cells with 5 μg/ml 
actinomycin D (Sigma A-4262) for 1 h followed by treatment with thapsigargin (0.2 μM) 
for different times. Total RNA was collected and the quantitative PCR method described 
above was employed to measure levels of VEGFA gene transcripts. The relative amount 
of each transcript was calculated by a standard curve of cycle thresholds for serial 
dilutions of cDNA sample and normalized to the amount of actin. Time point zero for 
each condition was standardized to 1 and the subsequent rate of degradation of mRNA 
was measured. 
Luciferase assay 
Mouse VEGFA 1 Kb (-1039 to 0) promoter and 3.3Kb Intron (460 bp Exon 1 + 
2891bp Intron 1) was cloned from Mouse BAC clone RP23 (Invitrogen, Carlsbad, CA) 
into the Xho1/HindIII site of pGL3 luciferase vector (Promega, Madison, WI). 293T cells 
were transfected with both reporters as well as mock pGL3 vector along with ATF4, 
processed-XBP1, processed-ATF6 (Δ373) and ATF5  by Lipofectamine™ 2000 
(Invitrogen, Carlsbad, CA). Twenty-four hrs post-transfection, lysates were prepared 
using a Luciferase Assay System kit (Promega, Madison, WI) according to the 
manufacturer’s protocol. The light produced from the samples was read by a standard 
plate reading luminometer. Each sample was read in triplicate and normalized against the 
signal produced from mock wells. β-galactosidase activity was measured by β-Gal 
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reporter gene assay kit (Roche Diagnostics, Mannheim, Germany). The assay was 
performed independently three times.  
Chromatin immunoprecipitation (ChIP) 
Mouse neuro2a cells were transfected with pFlag-CMV-2 (mock), processed-
XBP1 or processed-ATF6(Δ373) expression plasmid with HA-tag by Lipofectamine™ 
2000 (Invitrogen, Carlsbad, CA). After 24 hrs, cells were treated with or without 
thapsigargin for a further 6 h and fixed in 1% formaldehyde. ChIPs were performed using 
SimpleChIP™ Enzymatic Chromatin IP Kit (Agarose Beads) (Cell Signaling, Danvers, 
MA) as per the manufacturer’s recommendation. Anti-XBP1 antibody from Santa Cruz 
Biotechnology (Santa Cruz, CA), monoclonal anti-HA antibody from Roche Diagnostics 
(Indianapolis, IN) and negative control, rabbit IgG, were used for the ChIP assay. 
Purified DNA from cross-linked cells was dissolved in 50 μl TE; 2 μl was used for PCR. 
Inputs consisted of 10% chromatin before immunoprecipitation. Quantitative PCRs were 
performed as described in Quantitative polymerase chain reaction section using 
following primer set for mouse VEGFA promoter; forward: 
ATTCCTGGGAAAGGGAATTG and reverse: TCCACGGCCTCAAAATTATC. 
ELISA 
WT, Ire1α-/- and IRE1α rescued mouse embryonic fibroblasts were treated with 
media without glucose as indicated. Both supernatant medium as well as whole cell 
lysates were collected. Mouse VEGF secreted protein from supernatant and lysates were 
measured via ELISA analysis using Bio-Plex 200 System (BioRad, Hercules, CA) at the 
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UMass Mouse Phenotyping Center at University of Massahusetts Medical School, 
Worcester, MA. 
Ire1α+/- animals 
Ire1α+/+ and Ire1α+/- mice on 129 backgrounds are maintained at the animal 
medicine core at UMass Medical School (Worcester, MA). 
TUNEL assay 
Apoptotic cell death was assessed by TUNEL assay. The DeadEnd Colorimetric 
TUNEL System (Promega, Madison, WI) was used to stain apoptotic cells. 
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Results 
ER stress occurs in secretory cells and can increase VEGFA expression 
The endoplasmic reticulum (ER) is responsible for the early steps of folding of 
nascent polypeptides, post-translational modifications and prevention of aggregation 
during maturation of secretory proteins. When the influx of unfolded polypeptides 
exceeds the folding and processing capacity of the ER, it disrupts the ER homeostasis and 
causes ‘ER Stress’. Under these conditions, an ER-to-nucleus signaling pathway called 
the Unfolded Protein Response (UPR) is activated to relieve the stress, increasing the 
folding capacity as well as controlling the synthesis of new proteins. In mammals, 
secretory cells such as antibody-secreting plasma cells, hepatocytes and pancreatic β-cells 
show enhanced UPR activity in their development and function (206). Data from our lab 
shows the presence of high amounts of active spliced XBP1 in secretory organs where a 
large amount of proteins are produced such as the pancreas, liver and the embryonic day 
10.5 old mouse placenta, as compared to other tissues, suggesting a role for the UPR in 
these tissues (Figure 2.2A).   
One of these secreted proteins is vascular endothelial growth factor isoform A 
(VEGFA) which is an essential mediator of angiogenesis both in normal embryonic 
development as well as in solid tumors (161). Previous studies have shown that VEGFA 
is upregulated in human retinal ARPE-19 cells when treated with tunicamycin, an ER 
stress inducer (207). We wanted to check whether ER stress is accompanied by increased 
VEGFA expression in other cell types including cancer cells. Hence we treated the 
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human prostate cancer cell line, PC-3, human liver cancer cell line, HepG2, and the rat 
insulinoma cells, INS-1 832/13, with two ER stress inducers, thapsigargin and 
tunicamycin for 4 hr (Figure 2.2B). We found that VEGFA mRNA expression was 
increased 2-5 fold by ER stress. We confirmed that these cells were under ER stress by 
measuring expression levels of typical ER stress markers, spliced XBP-1 and BiP. 
HIF1α is not involved in ER stress-mediated VEGFA induction 
HIF1α is a major transcriptional regulator of VEGFA mRNA expression under 
hypoxia (208). Binding of HIF to the promoter of VEGFA is a key step in determining 
VEGFA activity (184). To test if HIF1α is involved in ER stress-mediated VEGF mRNA 
induction, we treated HepG2 cells with either the ER stress inducer thapsigargin or 
hypoxia, and then measured HIF1α protein expression. HIF1α protein expression by 
thapsigargin treatment was much lower than that by hypoxia (Figure 2.3A), raising the 
possibility that HIF1α is not involved in ER stress-mediated VEGFA induction. To test 
this possibility, we knocked down HIF1α expression using siRNA directed against 
HIF1α in HepG2 cells, stimulated them with thapsigargin, and then measured VEGFA 
induction. As we predicted, siRNA-mediated knockdown of HIF1α did not affect 
VEGFA induction by thapsigargin (Figure 2.3B). These results strongly suggest that 
HIF1α is not a major regulator of VEGFA mRNA expression under ER stress conditions. 
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Figure 2.2. ER stress is active in secretory organs and associated with VEGFA 
expression. (A) Wild type 129/Sv mice were dissected for harvesting indicated organs. Total 
cell lysates were analysed by anti-XBP1 antibody showing the spliced active 55kD band. Ire1+/+ 
(wild type) mouse embryonic fibroblasts treated with tunicamycin (TM, 5 μg/ml) served as 
positive control for XBP1 splicing. (B) Expression levels of VEGFA, Spliced XBP1 and BiP 
were measured by quantitative PCR in PC3 cells, HepG2 cells and INS-1 832/13 cells following 
treatment with thapsigargin  (Tg, 1 μM), tunicamycin (Tm, 5 μg/ml) and untreated (UT) control 
for 4 hr (n=3, values are mean ± SD). 
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Figure 2.3. Hif1α  is not required for VEGFA induction under ER stress. (A) HepG2 
cells were treated with either thapsigargin (Tg, 1 μM) 5 hr or hypoxia (0.5% O2) for 24 hrs. 
Nuclear lysates were extracted and analyzed using anti-HIF1α and anti-XBP1 antibodies. Spliced 
Xbp1 (55 kD) band is shown here. (B) HepG2 cells were transfected with scramble (Control) or 
HIF1α siRNA. 18 hrs post-transfection, cells were treated with thapsigargin (Tg, 1 μM) for 4 hrs. 
Total mRNA was collected and expression levels of HIF1α and VEGFA were measured by 
quantitative PCR (n=3, values are mean ± SD).  
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IRE1α is required for VEGFA expression under ER stress 
IRE1α, a key regulator of the UPR, is involved in transcriptional regulation of 
genes upregulated by ER stress. It has been shown that IRE1α signaling is involved in 
VEGFA mRNA expression by glucose deprivation and hypoxia (146). Glucose 
deprivation is known to activate the UPR. We were therefore interested in determining 
whether IRE1α was required for VEGFA mRNA expression under ER stress conditions. 
VEGFA mRNA expression levels were significantly decreased in Ire1α-/- mouse 
embryonic fibroblasts (MEFs) as compared to those in control wild-type MEFs under 
various ER stress conditions, induced by thapsigargin (Figure 2.4A), tunicamycin (Figure 
2.4B), glucose-deficient media for 24 hrs (Figure 2.4C) and hypoxia (0.5% O2) (Figure 
2.4D). ER stress during hypoxia was confirmed in wild-type MEFs by measuring 
upregulation of spliced Xbp1 which was absent in Ire1α-/- cells (Figure 2.4D, right panel). 
Both chemical ER stress inducers as well as physiological ER stress inducers, like 
nutrient glucose deprived medium, are able to activate VEGFA expression which is 
attenuated in Ire1α-/- MEFs. It is interesting to note that even under hypoxia, VEGFA 
levels are attenuated in Ire1α-/- MEFs suggesting that HIF1-dependent VEGFA 
transcription is not able to rescue VEGFA expression in MEFs. 
To further confirm the relationship between IRE1α signaling and VEGFA mRNA 
induction, we established Ire1α-/- cells transduced with lentivirus expressing human 
IRE1α. To confirm that ectopically expressed IRE1α was functional, we treated wild-
type, Ire1α-/- and cells rescued with human IRE1α with thapsigargin and measured 
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spliced XBP1 and phosphorylated IRE1α, indicators of IRE1α signaling activity. Spliced 
XBP1 levels were restored nicely as seen in an immunoblot of nuclear extracts from 
treated cells, indicating that ectopically expressed IRE1α was functional. Phosphorylated 
IRE1α was also restored indicating that IRE1α kinase activity is restored in rescued cells 
(Figure 2.5A). IRE1α protein levels are shown in an immunoblot of cytoplasmic extracts 
from the same cells. In Ire1α-/- cells rescued with human IRE1α, VEGFA mRNA 
expression was restored under ER stress conditions (Figure 2.5B). Complete restoration 
of IRE1α-XBP1 pathway similar to wild-type levels was not obtained from three 
different transduced pools of Ire1α-/- MEFs. However, partial rescue of VEGFA levels 
shows that its expression is proportional to the amount of spliced-XBP1 being produced. 
To determine whether IRE1α-mediated regulation of VEGFA expression affected 
expression of VEGF protein levels as well as its secretion outside the cell, we treated 
wild-type, Ire1α-/-  as well as the Ire1α-/- rescued MEFs with media lacking glucose for 24 
hrs. Nutrient deprivation causes ER stress and can upregulate VEGFA as seen in Figure 
2.4C. Analysis of cell protein lysate and supernatant VEGF protein reveals that 
expression as well as secretion of VEGF was restored in the rescued cells (Figure 2.6). 
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Figure 2.4. ER stress induced VEGFA upregulation is dependent on IRE1α. WT and 
Ire1α-/- mouse embryonic fibroblasts (MEFs) were treated with ER stress inducers thapsigargin 
(Tg, 1 μM) 5 hr (A), tunicamycin (Tm, 5 μg/ml) 5 hr (B) or kept in media without glucose for 
24hrs (C). Total RNA was collected and VEGFA mRNA expression levels were measured by 
quantitative PCR (n=3, values are mean ± SD). (D) WT and Ire1α-/- mouse embryonic fibroblasts 
(MEFs) were treated with hypoxia (0.5% O2) for 24 hr. Total RNA was collected and VEGFA 
and spliced XBP1 expression levels were measured by quantitative PCR (n=3, values are mean ± 
SD). 
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Figure 2.5 IRE1α is essential and sufficient for ER stress-mediated VEGFA 
upregulation. (A) Ire1α-/- MEFs were stably transduced with LV/Ire1α or LV/GFP, a lentivirus 
constitutively expressing human IRE1α or GFP. These cells along with WT and Ire1α-/- MEFs 
were treated with thapsigargin (Tg, 1 μM) for 5 hrs. Cytoplasmic lysates were analyzed using 
anti-IRE1α and anti-phosphorylated activated IRE1α (P-IRE1α) antibodies. Nuclear lysates were 
extracted and analyzed by anti-XBP1 to show rescue of IRE1 signaling pathway (55kD spliced 
form shown here) and anti-CHOP antibodies. (B) Total RNA from WT, Ire1α-/- and Ire1α-/- 
rescued MEFs treated with or without thapsigargin (Tg, 1 μM) for 5 hrs was analyzed for 
VEGFA and spliced XBP1 expression levels (n=3, values are mean ± SD). 
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Figure 2.6. IRE1α is required for VEGF protein synthesis and secretion under ER 
stress. WT, Ire1α-/- and Ire1α-/- rescued MEFs were kept in media with or without glucose for 24 
hrs. Supernatant medium as well as whole cell lysates were collected and analyzed for VEGF 
protein concentration by ELISA. 
 
 
 
71 
 
 
IRE1α regulates VEGFA expression in labyrinthine trophoblast cells 
Data from our lab as well as others have shown that Ire1α-/- mice are embryonic 
lethal by embryonic day 12.5 (27, 194, 209). It has been reported that the embryonic 
lethality of Ire1α-/- mice is due to the defect in the development of the placenta that is 
critical for integration and exchange between fetal and maternal blood vessels (194). We 
also observed that the UPR is highly active in the placenta (Figure 2.2A), thus indicating 
that ER stress plays a role in the growing placenta. It has previously been shown that loss 
of a single Vegfa allele in mice can result in embryonic lethality by embryonic day 9.5 
due to a defect in the development of labyrinthine trophoblast region of the placenta. This 
region plays a crucial role in exchange of growth factors, nutrients and wastes between 
maternal and fetal blood vessels (173). We therefore considered the possibility that 
IRE1α has a role in the survival of labyrinthine trophoblast cells through the activation of 
VEGFA expression. We found that Ire1α-/- placentas failed to develop proper 
labyrinthine trophoblast on embryonic day 10.5 (Figure 2.7A). When the labyrinthine 
sections were subjected to TUNEL staining, we found evidence of apoptosis in the 
labyrinthine layer of Ire1α-/- placenta but not in the wild-type placenta (Figure 2.7B). 
Because of the progressive loss of blood vessels in the labyrinthine layer, Ire1α-/- 
embryos are deprived of proper nutrition and growth factors and were comparatively 
smaller in size than wild-type embryos and did not survive more than embryonic day 12.5 
(Figure 2.7C). Table 1 shows the Ire1α-/- survival data. As can be seen, Ire1α-/- animals do 
not survive beyond embryonic day 12.5. To confirm the role of IRE1α signaling in 
mouse labyrinthine trophoblast cells, we also analyzed the mouse labyrinthine 
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trophoblast cell line, SM10 (210). These cells are derived from the labyrinthine 
trophoblast of wild-type embryonic d 9.5 mouse placenta. These cells responded robustly 
to ER stress inducers, tunicamycin and thapsigargin as well as 2-deoxy glucose which 
causes glucose deprivation, as indicated by upregulation of spliced XBP1 and CHOP 
protein expression levels (Figure 2.8, upper panel). VEGFA mRNA was also induced 
significantly upon ER stress (Figure 2.8, lower panel). Embryonic development is 
accompanied by activation of HIF1α in the growing placenta (202). This is required for 
proper growth and differentiation of endothelial cells in the placenta. We had already 
observed that HIF1α does not mediate ER stress-induced VEGFA expression (Figure 
2.3). To confirm that HIF1α was not involved in ER stress-mediated VEGFA mRNA 
induction in SM10 cells, we knocked down HIF1α expression by siRNA and measured 
VEGFA mRNA expression upon treatment with thapsigargin. As expected, RNAi-
mediated knockdown of HIF1α did not affect VEGFA mRNA induction by thapsigargin 
treatment in SM10 cells (Figure 2.9).  
We next sought to verify that ER stress-mediated VEGFA mRNA induction 
required IRE1α in SM10 cells. We transduced SM10 cells with lentivirus expressing a 
kinase inactive K599A mutant form of IRE1α that has been reported to act as a 
dominant-negative of wild-type IRE1α (37, 106), or GFP as a control, then we induced 
physiological ER stress using glucose deprivation which normally occurs during placenta 
development (201-203). In cells expressing kinase inactive K599A mutant form of IRE1, 
VEGFA mRNA levels were decreased as compared to control cells expressing GFP 
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(Figure 2.10). The suppression of IRE1α signaling by the kinase inactive IRE1α K599A 
mutant was confirmed by the attenuation of XBP-1 splicing (Figure 2.10). Previously it 
was reported that Ire1α-/- placenta have impaired VEGFA, but it was not shown in which 
specific layer of the placenta VEGFA deficiency occurs and thus presents the defective 
phenotype. Our results in the SM10 cells indicate that IRE1α has an essential function in 
VEGFA expression in the labyrinthine trophoblast cells and thereby is crucial for normal 
angiogenesis and development of placenta. Our results also point out that the IRE1α 
signaling pathway is independent of HIF1α activity.  
 
 
 
 
 
74 
 
 
 
Figure 2.7. Ire1α-/- mouse placenta have a defective labyrinth. (A) WT and Ire1α-/- 
placenta were collected at E10.5 and vertically dissected and HE stained to show all placenta 
layers from maternal decidua to fetal chorionic plate SP= Spongiotrophoblast, LA= Labyrinthine 
trophoblast. (B) WT and Ire1α-/- placenta collected at E11.5 were vertically dissected and TUNEL 
stained to show apoptosis in labyrinthine layer. (C) WT and Ire1α-/- embryo littermates were 
collected from Ire1α+/- females mated with Ire1α+/- males. Ire1α-/- animals die by embryonic day 
12.5. 
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Table 1.  Mouse embryo survival data. 
Age (days) total (+/+) (+/-) (-/-) resorbed
E 8.5 35 4 (11%)   21 (60%)  8 (23%)   2 
E 9.5 34 8 (24%)   19 (56%)  4 (12%)   3 
E10.5 84 19 (23%)  45 (54%)  15 (18%)  5 
E11.5 34 8 (24%)   17 (50%)  6 (18%)   3 
E12.5 33 7 (21%)   14 (42%)  2 (6%)      10 
E13.5 25 6 (24%)   14 (56%)  2 (8%)    3 
 
Ire1+/- heterozygous animals were crossed and embryos as well as placenta were collected at 
various stages of development starting at embryonic day 8.5. 
 
 
76 
 
 
 
 
Figure 2.8 SM10 cells respond to ER stress. Labyrinthine trophoblast SM10 cells were 
treated with thapsigargin (Tg, 1 μM) tunicamycin (Tm, 5 μg/ml) or 2-deoxy-glucose (2 DG) for 6 
hrs. Total cell lysates and mRNA were collected.  Lysates were analyzed by anti-XBP1 showing 
the spliced active 55 KD band, and anti-CHOP antibody (upper panel). Total RNA was used for 
expression analysis of VEGFA (lower panel) (n=2, values are mean ± SD). 
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Figure 2.9. VEGFA upregulation under ER stress is not mediated by HIF1α in 
SM10 cells. SM10 cells were transfected with scramble (Control) or HIF1α siRNA. 18 hrs post-
transfection, cells were treated with thapsigargin (Tg, 1 μM) for 4 hrs. Total RNA was collected 
and expression levels of HIF1α and VEGFA were measured by quantitative PCR (n=3, values are 
mean ± SD). 
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Figure 2.10. IRE1α regulates VEGFA expression in SM10 cells under ER stress. 
SM10 cells were stably transduced with either LV/control GFP or LV/Ire1KA mutant lentivirus 
to constitutively express GFP or IRE1KA protein. Transduced stably expressing cells were kept 
in media with or without glucose for 24 hrs. Total RNA was then analyzed for VEGFA and 
spliced XBP1 (n=2, values are mean ± SD).   
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IRE1α does not have a role in stabilization of VEGFA mRNA 
Our next goal was to understand how IRE1α regulates VEGFA under ER stress. 
Post-transcriptional regulation of VEGFA had been reported previously. It was shown 
that VEGFA is stabilized by hypoxia-mediated binding of AU-rich elements (AREs) (that 
are responsible for targeting the mRNA for degradation) in the 3’-untranslated region 
(UTR) of VEGF mRNA by the RNA-binding protein, HuR (191). The presence of 
internal ribosome entry site (IRES) sequences in the 5’-non-coding region of VEGFA 
mRNA  also help in cap-independent translational initiation of VEGFA under both 
hypoxia and nutrient deprivation (192). Stress-activated protein kinases JNK and p38 
have been shown to increase VEGF mRNA expression by interacting with the VEGF 3’ 
UTR (193). Because IRE1α can activate the JNK signaling pathway under chronic ER 
stress, we tested whether IRE1α is involved in VEGFA mRNA stability. We used 
actinomycin D to attenuate mRNA transcription, then challenged Ire1α-/- and control 
wild-type MEFs with thapsigargin and looked at the rate of VEGFA mRNA decay. We 
found that IRE1α was not involved in ER stress-mediated VEGFA mRNA decay as there 
was no appreciable difference in VEGFA mRNA expression levels between the two cell 
types (Figure 2.11).  
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Figure 2.11. IRE1α does not affect VEGFA mRNA stability. WT and Ire1α-/- MEFs were 
treated with or without actinomycin D (5 μg/ml) for 1 hr. Cells were then treated with 
thapsigargin (Tg, 0.2 μM) for 0, 1.5 or 3 hrs. Total RNA was collected and expression levels of 
VEGFA were measured by quantitative PCR (n=3, values are mean ± SD). 
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IRE1α upregulates VEGFA expression via XBP1 
IRE1α mediates XBP1 mRNA splicing, which leads to production of an active 
transcription factor called spliced XBP1 (XBP1s). XBP1s has a role in upregulation of a 
broad range of UPR target genes many of which are involved in protein folding, ER-
associated degradation, ER protein quality control. It also regulates the expansion of the 
secretory pathway by controlling ER/Golgi biogenesis and phospholipid biosynthesis (34, 
43). XBP1 has also been suggested to have a role in tumor growth (142). Hence, it might 
be possible that XBP1s is involved in the regulation of VEGFA mRNA expression under 
ER stress conditions. To test this idea, we measured expression levels of VEGFA in 
Ire1α-/- MEFs transfected with mouse processed-XBP1 (XBP1-p) plasmid which 
constitutively expresses the spliced form of XBP1. Ectopic expression of XBP1s restored 
VEGFA induction in Ire1α-/- MEFs under ER stress conditions (Figure 2.12, upper 
panel). Although expression levels of VEGFA and spliced XBP1 were lower in Ire1α-/- 
MEFs ectopically expressing XBP1s and IRE1α as compared to control wild-type MEFs, 
the degree of VEGFA mRNA induction was strongly correlated with an increase in 
spliced XBP1 mRNA expression (Figure 2.12, lower panel), suggesting that XBP1s-
mediated induction of VEGFA is dose-dependent. To further confirm this idea, we 
compared expression levels of VEGFA in the hepatocellular carcinoma cell line, HepG2, 
transfected with siRNAs directed against IRE1α, XBP1, or control scramble siRNA 
under ER stress induced by thapsigargin. We found that, VEGFA mRNA induction was 
attenuated in the cells transfected with IRE1α siRNA and XBP1 siRNA as compared to 
the cells transfected with control scramble siRNA (Figure 2.13). Suppression of IRE1 and 
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XBP1 signaling was confirmed by the downregulation of EDEM, which is a known 
downstream effector of XBP1 (47). These results, taken together, tell us that IRE1α can 
regulate VEGFA upregulation under ER stress through its downstream effector, XBP1. 
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Figure 2.12. IRE1α regulates VEGFA under ER stress through spliced XBP1. Ire1α-/- 
MEFs transfected with processed-XBP1 (Xbp1-p) along with WT, Ire1α-/- and Ire1α-/- MEFs 
overexpressing IRE1α protein were treated with thapsigargin (Tg, 1 μM) for 5 hrs. Total RNA 
was analyzed for VEGFA and spliced XBP1 expression levels (n=3, values are mean ± SD). 
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Figure 2.13. IRE1α regulates VEGFA through spliced XBP1. HepG2 cells were 
transfected with scramble (Control), IRE1α siRNA or XBP1 siRNA. 18 hrs post-transfection, 
cells were treated with thapsigargin (Tg, 1 μM) for 4 hr. Total RNA was collected and VEGFA, 
spliced XBP1 and EDEM expression levels were measured by quantitative PCR (n=3, values are 
mean ± SD).   
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XBP1s controls VEGFA by binding its promoter under ER stress 
XBP1s binds the unfolded protein response element (UPRE) with a highly 
conserved ACGT core (40, 41) or the CCACG box which is part of the composite ER 
stress Response Element (175) in the promoters of its target genes (211). The VEGFA 
promoter region contains one putative XBP1s binding site, the ACGT core, 972 bp 
upstream of the mouse VEGFA start site, raising the possibility that XBP1s binds to 
VEGFA promoter. To test this idea, we derived a reporter construct by cloning 1 kb 
upstream sequences of the mouse VEGFA transcription start site upstream of the 
luciferase gene. Ectopic XBP1s expression by way of transfection of processed-XBP1 
plasmid increased activity of VEGFA promoter-luciferase reporter (Figure 2.14). 
However, ATF4, which is a downstream effector of PERK signaling pathway, does not 
show as much increase as XBP1. It should be noted that ATF4 also plays a role in 
VEGFA expression under ER stress but its mechanism is different, which will be 
explained in the next chapter.  
In order to establish a direct interaction of XBP1 with VEGFA promoter, we did a 
chromatin immunoprecipitation (ChIP) analysis of the mouse VEGFA promoter. Since 
we were looking at mouse VEGFA gene, we chose the mouse neuro2A cell line to 
observe XBP1-VEGFA promoter binding. We first tested whether these cells show 
VEGFA mRNA upregulation upon ER stress. We found that they show upregulation of 
VEGFA mRNA under ER stress (Figure 2.15). Mouse neuro2A cells were then either 
mock transfected or transfected with processed XBP-1-p (XBP1s), and treated with 
thapsigargin. Because XBP1 has a putative binding site at -972 bp upstream of start site, 
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we chose PCR primers starting from -932 bp upstream of the mouse VEGFA 
transcription start site to yield a 144 bp PCR product for ChIP analysis. We found that 
XBP1 was recruited to the mouse VEGFA promoter under ER stress conditions in the 
mock transfected cells (Figure 2.16). XBP-1-p overexpression improves binding 
efficiency which is further increased by ER stress thus supporting the idea of dose-
dependent upregulation of VEGFA transcription under ER stress. Collectively, these 
results show that VEGFA is a direct target of the IRE1α-XBP1 pathway. 
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Figure 2.14. XBP1s activates VEGFA promoter. Luciferase activity in 293T cells 
transfected with VEGFA-promoter reporter (pGL3/VEGF-1039/0) or control pGL3 mock constructs 
along with indicated plasmids and control PCDNA3 vector (values are mean ± SD). Xbp1-p 
represents spliced constitutively active form of XBP1 transcription factor. Top diagram shows 
schematic of mouse VEGFA gene as well as size of mouse VEGFA promoter construct.   
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Figure 2.15. Mouse neuro2A shows ER stress-mediated VEGFA upregulation. Mouse 
neuro2A cells were treated with thapsigargin (Tg, 1 μM) for 0, 6, 12 and 24 hrs. Total RNA was 
collected and VEGFA expression levels were measured by quantitative PCR (n=3, values are 
mean ± SD).   
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Figure 2.16. XBP1s binds VEGFA promoter efficiently under ER stress. Chromatin IP 
product using anti-XBP1 or control IgG antibody in mouse neuro2a cells transfected with either 
mock pFlag-CMV-2 or processed-Xbp1-p constructs and treated with or without thapsigargin 
(Tg, 1 μM) for 6 hrs was analyzed using quantitative PCR. PCR primer pair corresponded to 
mouse VEGFA promoter segment. Fold enrichment was quantified using ratio of amplification of 
PCR product relative to 10% input DNA. Value obtained from mock was defined as 1(n=3, 
values are mean ± SD). 
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ATF6α also plays a role in VEGFA mRNA upregulation under ER stress 
ATF6α, an ER transmembrane protein, is another upstream component of the 
UPR. Under ER stress conditions ATF6α translocates from ER to the Golgi where its 
cytoplasmic domain is cleaved from the membrane to produce a potent transcription 
factor regulating UPR target genes (2). XBP1 is one of the targets of cleaved-ATF6α 
(31). Induction of XBP1 mRNA by ATF6 is an important step in the ER stress signaling 
mechanism. Detection of spliced-XBP1 in ER stressed cells is always preceded by the 
active nuclear form of ATF6α, thus emphasizing a close association of these two UPR 
effectors(31). Active spliced-XBP1 heterodimerizes with cleaved-ATF6 to induce ER 
chaperones as well as ERAD components through more efficient binding of the ERSE as 
compared to XBP1 homodimers. Deficiency of ATF6α has been reported to increase 
sensitivity to chronic ER stress. Hence, we tested whether ATF6α was involved in 
VEGFA mRNA expression under ER stress conditions. As predicted, RNAi-mediated 
knockdown of ATF6α in HepG2 cells resulted in a significant decrease of VEGFA 
mRNA expression under ER stress conditions (Figure 2.17). These results suggest that 
ATF6α also plays a role in ER stress mediated VEGFA expression. 
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Figure 2.17. ATF6α regulates VEGFA mRNA expression under ER stress. HepG2 
cells were transfected with scramble (Control) and ATF6 siRNA and treated with thapsigargin 
(Tg, 1μM) for 4 hr. Total RNA was collected and VEGFA and ATF6 expression levels were 
measured by quantitative PCR (n=3, values are mean ± SD). 
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ATF6α regulates VEGFA promoter  
Association of spliced-XBP1 protein with cleaved ATF6α protein has been shown 
to efficiently activate downstream ER stress responsive elements (175) in UPR target 
genes. Hence we hypothesized that ATF6α might have a role to play in activating the 
VEGFA promoter because of its association with XBP1s under ER stress conditions and 
also because of its role in upregulating XBP1 mRNA expression. To further establish a 
relationship between ATF6α and VEGFA mRNA induction, we tested if ATF6α could 
increase the activity of gene regulatory regions of VEGFA gene. Ectopic expression of 
cleaved active ATF6α (ATF6Δ373) increased the activity of the same VEGFA-promoter 
reporter as described earlier (Figure 2.18A). This reporter had 1039 bp upstream 
sequence of mouse VEGFA containing the putative XBP1 binding motif at -972 bp 
upstream of transcription start site fused to the luciferase reporter.  Evidence presented in 
the next chapter shows that the PERK-ATF4 signaling arm of the UPR can regulate 
VEGFA by activating the first intron of VEGFA. Hence to check whether ATF6α-N 
(cleaved) as well as XBP1s activates VEGFA intron, we used a reporter which has both 
the 2891 bp intron 1 as well as the 460 bp exon1 fused to the luciferase gene. We found 
that ATF6α does not bind the VEGFA intron 1 as can be observed  by VEGF-intron 1 
reporter activity when compared to ATF4 (Figure 2.18B). Collectively, these results 
strongly suggest that ATF6α also plays a role in VEGFA mRNA induction by activating 
its promoter under ER stress conditions. 
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Figure 2.18. ATF6 activates VEGFA promoter. (A) Luciferase activity in 293T cells 
transfected with VEGFA-promoter reporter (pGL3/VEGF-1039/0) or control pGL3 mock constructs 
along with indicated plasmids and control pHA vector (values are mean ± SD). ATF6(Δ373) 
represents a cleaved constitutive active form of ATF6 transcription factor. Xbp-1-p and ATF5 
represent positive and negative controls respectively. (B) Luciferase activity in 293T cells 
transfected with mouse VEGFA-intron 1 reporter (pGL3/VEGF0/+3351) or control pGL3 mock 
constructs along with indicated plasmids and control pHA vector (values are mean ± SD). ATF4 
and ATF5 serve as positive and negative controls respectively. 
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ATF6 binds VEGFA promoter under ER stress 
The preceding result prompted us to ask the question whether ATF6α also binds 
the promoter in order to activate VEGFA expression. In order to demonstrate a direct 
interaction of ATF6α with VEGFA, we did a chromatin immunoprecipitation (ChIP) 
analysis of the mouse VEGFA promoter. Because of the absence of a ChIP validated 
antibody for ATF6α, we transfected mouse neuro2A cells with ATF6α(Δ373) (cleaved 
active ATF6-N) which has an HA-tag on it. After 24 hrs of transfection, cells were 
treated with thapsigargin for 6hrs. Chromatin IP was done using anti-HA antibody or 
control IgG antibody on both treated and untreated cells. ChIP PCR was performed using 
the same primers used for XBP1 ChIP analysis that correspond to -932 bp upstream of 
VEGFA transcription start site. ChIP analysis indicates that ATF6 was recruited to the 
mouse VEGFA promoter under ER stress conditions in vitro (Figure 2.19). Cleaved 
ATF6α binding efficiency was increased by ER stress thus supporting the idea of ATF6α-
mediated VEGFA transcription under ER stress. These results show that ATF6α plays a 
role in binding the VEGFA promoter to activate its transcription. This binding might be 
through its heterodimerization with XBP1s as the VEGFA promoter lacks a classical 
ERSE motif that is recognized by cleaved ATF6α transcription factor. 
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Figure 2.19. ATF6 binds VEGFA promoter. Chromatin IP was performed in mouse 
neuro2a cells transfected with ATF6 (Δ373) plasmid treated with or without thapsigargin (Tg, 1 
μM) for 6 hrs using anti-HA or control anti-IgG antibodies. ATF6 recruitment was analyzed by 
quantitative PCR of ChIP products. PCR primer pair corresponded to mouse VEGFA promoter 
segment (PCR product size was 144 bp starting at -932 upstream of transcription initiation site). 
Fold enrichment was quantified using ratio of amplification of PCR product relative to 10% input 
DNA. Value obtained from mock was defined as 1(n=3, values are mean ± SD). 
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Discussion 
IRE1α is a primary regulator of the unfolded protein response signaling pathway 
that contributes to both homeostatic and apoptotic outputs. Homeostasis is maintained 
under ER stress by activation of the downstream transcription factor XBP1 that can 
activate genes involved in the proper folding of nascent polypeptides as well as the 
ERAD pathway that helps in the degradation of misfolded proteins, thus maintaining ER 
quality control. This homeostatic effect of IRE1α also has been reported to help in cell 
fate determination and differentiation via XBP1 (42). Apoptosis can be activated by 
IRE1α by binding the adaptor protein TNF receptor-associated factor 2 (TRAF2), an E3 
ubiquitin ligase. This leads to activation of apoptosis signal-regulating kinase 1 (ASK1), 
which in turn activates the JNK signaling pathway (27, 92). Also, the proapoptotic BCL-
2 family members, BAX and BAK can physically interact and activate IRE1α thereby 
promoting IRE1α signaling (93). Here we show the homeostatic effect of IRE1α by 
promoting ‘angiogenesis’ through VEGFA upregulation under ER stress. Angiogenesis is 
required by the growing vasculature to cope with unfavorable environmental conditions 
of hypoxia, nutrient deprivation, low pH, and is essential for cell survival. 
Angiogenesis is a crucial step in both normal development as well as growth of 
solid tumors. Proper development of blood vessels is absolutely essential for survival of a 
growing embryo, as well as for tumors to compensate for their insatiable need for 
nutrients and growth factors needed to survive the unfavorable environmental conditions. 
VEGFA has been by far the most studied angiogenic factor in the field of cancer 
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research. In the developing fetus, the placenta also produces several growth hormones 
like placental lactogens, tissue remodeling factors like matrix metalloproteinases (MMPs) 
and angiogenic factors like VEGF (201). The production of a large number of proteins 
requires an efficient UPR and the placenta definitely shows an active UPR as we could 
see from the high expression of XBP1s in this tissue. The proper expression of these 
factors is required for development of the placenta and any defect in their expression can 
lead to placental insufficiency, fetal growth retardation and death. Ire1α-/- animals show 
these defects. VEGFA expression is much higher in the growing placenta as compared to 
the embryo in the mid-gestational stage (195). VEGFA expression is also higher in the 
labyrinthine trophoblast. Finally, VEGFA heterozygous mice are embryonic lethal by E 
10.5, thereby underscoring its importance to normal vascular development. All of this 
evidence naturally suggested that there was a relationship between IRE1α and VEGFA.  
We found that Ire1α-/- mouse embryonic fibroblasts had a significantly lower 
expression of VEGFA mRNA as compared to wild-type cells. This was also shown by 
another group in tumor cell lines (146). They also reported that dominant-negative IRE1 
expressing tumors were of smaller size and more sensitive to ER stress. Here we show 
that rescue of IRE1α in the knockout MEFs restores VEGFA mRNA levels fully. The 
question remained whether the difference in VEGFA mRNA levels also translated to a 
difference in protein levels as well as secretion. Our data reveals that both protein as well 
as secretion levels are attenuated in Ire1α-/- MEFs and are nicely restored in the rescued 
cells. 
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The relationship between IRE1α and VEGFA has not been studied in detail till 
now. IRE1α signals the upregulation of UPR target genes through the unique splicing of 
XBP1 mRNA by its endoribonuclease domain. XBP1 has been shown in some studies 
done at the Koong lab to be important for survival of tumors under hypoxic stress. These 
studies have also shown that tumor survival  is not dependent on hypoxia signaling (142). 
This matches with our results as we have shown that HIF1α is not required for VEGFA 
expression under ER stress. We also found that VEGFA expression levels are attenuated 
even under hypoxic stress. Thus, the UPR-activated IRE1α pathway is a crucial regulator 
of VEGFA which is independent of HIF1α signaling. However, this group also reports 
that basal VEGF protein secretion levels were similar between XBP1-deficient and wild-
type cells under hypoxic conditions. This suggests an XBP1-independent regulation of 
VEGFA by IRE1α. But our data in Ire1α-/- and rescued MEFs show that VEGFA 
secretion is dependent on IRE1α-XBP1 pathway. We found that XBP1-deficiency leads 
to VEGFA mRNA attenuation and that the Ire1α-/- MEF VEGFA phenotype can be 
rescued by over expression of spliced form of XBP1 in a dose-dependent manner under 
ER stress. Thus, our results show that VEGFA upregulation under ER stress is dependent 
on the spliced XBP1 arm of IRE1α. 
The JNK/SAPK signaling pathway has been shown to have a role in VEGFA 
mRNA stability through its interaction with the 3’UTR (193). Because IRE1α can also 
activate the JNK signaling pathway under excessive ER stress conditions, we looked to 
see if IRE1α activation by ER stress stabilizes VEGFA mRNA. VEGFA mRNA decay 
rates between IRE1α-deficient and wild-type MEFs are similar, thereby ruling out 
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involvement of post-transcriptional regulation of VEGFA. Thus VEGFA is regulated by 
IRE1α at the transcriptional level. 
XBP1 binds the GACGTG box that comprises the unfolded protein response 
element (UPRE) with a highly conserved ACGT core (40, 41) or the CCACG box which 
is part of the composite ER stress response element in the promoters of its target genes 
(42). When we looked at the VEGFA promoter, we found an ‘ACGT’ core element 972 
bp upstream of the mouse VEGFA start site. It should be noted that the hypoxia response 
element (HRE) of the mouse VEGFA promoter is 1542 bp upstream of start site. We 
found that the 1kb VEGFA upstream reporter showed increased luciferase activity in 
presence of spliced XBP1, suggesting that XBP1s must be regulating VEGFA promoter 
independently. Our ChIP data clearly shows that XBP1s binds the VEGFA promoter 
under ER stress. We already know that IRE1α activates XBP1 by splicing its mRNA to 
produce XBP1s protein under ER stress. We found that overexpression of XBP1s shows 
better enrichment which is even more increased under ER stress as detected by the anti-
XBP1 antibody for ChIP analysis. This suggests that binding efficiency increases when 
XBP1s population increases under ER stress due to IRE1α activity, thereby upregulating 
VEGFA mRNA levels. Hence our data clearly defines the mechanism of VEGFA 
upregulation by IRE1α under ER stress. 
The only component of the UPR that has not yet been directly linked to tumor 
growth is ATF6α. Here we find that ATF6α is required for VEGFA expression under ER 
stress. Previous microarray analysis of ATF6α had revealed that it is primarily involved 
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in the ER quality control processes by regulating ER chaperones and ERAD components. 
It has also been linked to cancer because of its effect on resistance to the drug rapamycin 
(157). One of the most important functions of ATF6α is the dimerization of its cleaved 
active form with the spliced active XBP1 to form a potent activator of ERAD 
components (44). ATF6α is also required for the induction of XBP1 mRNA in response 
to ER stress (31). These observations and our experiments tell us that ATF6α works 
closely with XBP1 to regulate downstream effectors, VEGFA being one of them. When 
we looked at the VEGF-promoter as well as the intron, we found that maximum activity 
was shown by the VEGF-promoter in the presence of cleaved active ATF6. Hence, we 
hypothesize that active ATF6 dimerizes with spliced XBP1 protein in order to regulate 
VEGFA transcription. Because maximum activity was shown by the promoter reporter, 
we did chromatin immunoprecipitation analysis of the promoter under ER stress 
conditions in cells overexpressing HA-tagged cleaved ATF6. As we predicted, binding 
efficiency was increased under ER stress conditions. This observation tells us that ATF6 
might be dimerizing with XBP1 and upregulating VEGFA by binding its promoter. 
Hence our study points to a novel function of ATF6α in which it regulates VEGFA under 
ER stress. 
Taken together, our findings in chapter II enable us to form a model of the role of 
the IRE1α-XBP1 and the ATF6α pathway in angiogenesis. When ER stress occurs due to 
adverse environmental conditions like hypoxia and nutrient glucose deprivation, the 
activation of IRE1α and cleavage of ATF6α leads to activation of XBP1 and ATF6α-N 
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(cleaved). Both XBP1s and ATF6α-N bind the promoter of VEGFA to upregulate 
VEGFA expression which then drives angiogenesis (Figure 2.20). 
The impact of this mode of regulation can be gauged from the fact that Ire1α-/- 
animals do not survive beyond 12 days due to loss of blood vessel development in the 
labyrinthine layer of the placenta. However, Atf6α-/- mice do not show the same 
phenotype. We think that this may be due to differential activation of the two pathways 
depending on cell type. Our observation suggests that IRE1α mediated VEGFA 
activation is crucial for labyrinthine trophoblast survival in the placenta but ATF6α is 
not. Hence our model is that the UPR and especially IRE1α activity is essential for 
normal growth and development of the fetus as well as tumorigenesis (Figure 2.20). Our 
study helps us understand the exact mechanism by which IRE1α and ATF6α affects cell 
survival and growth by regulating VEGFA and also lays out the possibility of targeting 
these pathways with novel chemotherapeutic agents to restrict tumor growth. 
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Figure 2.20. IRE1α and ATF6α are required for normal VEGFA expression under 
ER stress. Proposed model shows that IRE1α-XBP1 and the ATF6α signaling arm of the UPR 
activate the VEGFA promoter to upregulate VEGFA expression under ER stress. IRE1α-XBP1 
pathway is especially activated in the growing placenta. Proper expression of VEGFA is essential 
for normal angiogenesis as well as in tumorigenesis. 
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CHAPTER III: PERK IS ALSO REQUIRED FOR TRANSCRIPTIONAL 
REGULATION OF VEGFA EXPRESSION IN MAMMALIAN CELLS 
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Summary 
The PERK-eIF2α signaling pathway forms another crucial axis of the unfolded 
protein response to ER stress. This pathway has been shown earlier to be essential for 
survival under extreme environmental conditions like hypoxia. PERK is an ER 
transmembrane protein whose N-terminal ER luminal domain binds the ER chaperone 
BiP under normal conditions. Under ER stress, BiP is released and activates the 
dimerization and autophosphorylation of the cytoplasmic kinase domain which then 
phosphorylates the initiator molecule of protein synthesis, eIF2α, thereby inhibiting 
protein synthesis till the stress is relieved. This is another mode of UPR activity to 
maintain ER homeostasis. However, PERK can also preferentially activate a potent 
transcription factor, ATF4, via an alternate open reading frame to activate UPR target 
molecules that help to maintain homeostasis in response to ER stress. We show here that 
VEGFA expression under ER stress is also controlled by PERK. The mode of VEGFA 
transcriptional regulation is different from the IRE1α and the ATF6α pathways. We 
observed that PERK activates ATF4 under ER stress which then binds the first intron of 
the VEGFA gene and upregulates its expression. Thus, an alternate mode of VEGFA 
regulation by distinct UPR regulators gives the UPR tight control over VEGFA 
expression. We also show that knockdown of both IRE1α and PERK pathways can lead 
to more severe VEGFA attenuation, thereby underlining the role of the UPR in VEGFA 
regulation. 
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Introduction 
Double-stranded RNA-activated protein kinase (50)-like endoplasmic reticulum 
kinase (13) is an ER-resident type I transmembrane protein ubiquitously expressed but 
highly enriched in secretory cells like pancreatic β cells (13). PERK is associated with the 
ER chaperone BiP/GRP78 under normal conditions. ER stress leads to accumulation of 
unfolded proteins in the ER which competes for BiP resulting in its dissociation from 
PERK and stimulates its dimerization and autophosphorylation. Thus, this mechanism of 
activation seems to be conserved between PERK and IRE1(60). PERK is a member of a 
family of eukaryotic initiation factor kinases that reduce global protein translation in 
response to specific stress signals. The eIF2 complex recruits the initiator methionyl 
tRNA to ribosomes about to begin protein translation. Phosphorylation of serine-51 on 
the α-subunit of eIF2 complex by PERK under ER stress conditions inhibits this activity 
and thus reduces global protein synthesis (55, 63). 
Perk-/- mice are characterized by neonatal or early-infancy insulin-dependent 
diabetes, exocrine pancreas atrophy, skeletal dysplasia and growth retardation (61, 62). 
There is a progressive pancreatic islet β-cell death in the absence of PERK due to 
accumulation of unfolded proteins causing excessive ER stress. This indicates the 
importance of PERK in the proliferation and differentiation of insulin-secreting β-cells 
during fetal development. Similar symptoms are observed in the rare genetic disease, 
Wolcott-Rallison syndrome (56, 62). 
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 Phosphorylation of eIF2α also leads to activation of a transcription factor, 
activating transcription factor 4 (ATF4). This forms a second phase of enhanced 
expression of UPR genes after the initial repression of translation. While most of the 
RNA transcripts experience decreased translation because of eIF2α phosphorylation by 
PERK, ATF4 mRNA is translated more efficiently via a complex initiation process which 
involves two upstream open-reading frame (uORF) sequences (63). A gene expression 
microarray analysis of Perk-/- and Atf4-/- cells treated with the ER stress inducer, 
tunicamycin, revealed the impact of PERK and ATF4 on a wide variety of functions. The 
genes regulated by PERK are involved in folding and processing secretory proteins, the 
ERAD pathway for clearance of misfolded proteins, glutathione biosynthesis controlling 
the cellular redox status, amino acid synthesis and transport, regulation of apoptosis and 
transcriptional regulation. ATF4-controlled genes formed only a subset of the genes 
controlled by PERK with significant roles in amino acid metabolism, protection from 
oxidative stress, regulation of apoptosis and increased expression of bZIP transcription 
factors, ATF3 and CHOP (66). Different upstream eIF2α kinases under different types of 
stress can induce ATF4 transcription. For example, PERK can activate ATF4 under ER 
stress, but under amino-acid deprivation stress, PERK is dispensable and ATF4 is 
activated by another eIF2α kinase, GCN2 (66). ATF4 then associates with other 
transcription factors which are specific to each stress condition and independent of eIF2α 
phosphorylation and induces transcription of effector genes required to mitigate that 
stress. Under ER stress conditions, ATF4 functions in combination with the bZIP 
transcription factors XBP1 and ATF6 to direct the UPR. ATF4 function has been mainly 
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studied in the context of amino acid deprivation and oxidative stress-induced signaling. 
One of the best characterized promoters activated by ATF4 is asparagine synthetase 
(ASNS), which catalyses the biosynthesis of asparagine and glutamate. This promoter has 
two cis-acting elements designated as nutrient-sensing response element (NSRE)-1 and 2 
which are also known as amino acid response elements (AARE). ATF4 binds the NSRE-
1 in response to ER stress or amino acid deficiency (71) and recruits ATF3 and C/EBPβ 
in a complex two-step mechanism to drive ASNS transcription (72). This mechanism is 
thought to occur in most of the other ATF4-targeted promoters like ATF3, CHOP and 
VEGF which are induced by amino acid deficiency and the UPR.  
Studies in tumors have revealed that the PERK-eIF2α pathway plays an important 
role in protection from hypoxic stress. Hypoxia rapidly increases phosphorylation of 
eIF2α through activation of PERK as well as increasing ATF4 and CHOP levels, and 
transformed Perk-/- cells had lower survival rates under hypoxia (147). It should be noted 
that the ATF4 increase under hypoxia is dependent on PERK and not on the dominant 
HIF1 signaling pathway which is active under these conditions (148, 149). Angiogenesis 
was impaired in the tumors derived from Perk-/- transformed mouse embryonic 
fibroblasts which suggests that VEGFA might play a role here as it is the primary 
mediator of angiogenesis (151). Tumors derived from cells expressing dominant-negative 
PERK that are defective in eIF2α phosphorylation were smaller in size and had higher 
levels of apoptosis (150). Similar to Perk-/- cells, Atf4-/- mouse embryonic fibroblasts 
(MEFs) were more sensitive to hypoxia than wild-type MEFs, demonstrating higher 
levels of caspase-3, as well as failing to induce CHOP. This suggests that the PERK-
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eIF2α pathway has a beneficial role for the growing tumor and its pro-apoptotic activity 
through CHOP upregulation might be secondary to its pro-survival activity (147, 150, 
152). 
The first direct evidence that PERK might play a role in VEGFA regulation was 
found when a microarray analysis of Perk-/- cells showed an attenuation in VEGFA 
expression under hypoxic conditions as compared to wild-type MEFs (151). However, 
secreted VEGF levels are not statistically different between wild-type cells and cells with 
a non-phosphorylatable ‘knock-in’ mutation of eIF2α (S51A) under extreme hypoxia (≤ 
0.02%) (150). Interestingly, ATF4 has been found to regulate VEGFA expression under 
oxidative stress conditions which can activate the upstream eIF2α kinase, HRI. Thus, 
under a different kind of stress, namely, oxidative stress caused by arsenite, ATF4 binds a 
DNA element at +1767 bp relative to human VEGF transcription start site in the human 
retinal pigmented epithelial cell line ARPE-19 (197).  Also, homocysteine, a homolog of 
the amino acid cysteine which has been associated with age-related macular degeneration 
(AMD), has been shown to upregulate VEGF in ARPE-19 cells (198). However, the 
exact mechanism of activation has not been elucidated yet under ER stress conditions 
specifically.  
Preliminary experiments in our lab showed that Perk-/- MEFs had a significant 
attenuation of VEGFA under ER stress conditions. These observations as well as studies 
done before with IRE1α and ATF6α (as explained in the first chapter) made us wonder 
whether the UPR might have a broad role in VEGFA expression and synthesis. Because 
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VEGFA is a secreted protein and is required in large amounts for tumor cells to survive 
extreme conditions like hypoxia and nutrient deprivation, the UPR may be playing a role 
in the proper functioning of the ER to ensure that VEGFA is secreted under these 
conditions. We then asked the question how PERK regulates VEGFA. Is VEGFA 
regulated by PERK via its promoter or the intron? We hypothesized that PERK mediates 
its regulation of VEGFA via its downstream activator ATF4 which is preferentially 
upregulated under ER stress conditions. We were able to characterize the PERK-
mediated VEGFA regulation through ATF4. We also show that under ER stress produced 
by the chemical inducer thapsigargin, or when cells are treated with media deprived of 
glucose for long time periods there is increased VEGFA expression and its attenuation in 
Perk-/- cells is reversed if PERK expression is restored. Our results imply that the ER 
stress regulator PERK is integral to proper activation of VEGFA in secretory cells and its 
inactivation cannot be compensated by the other UPR regulators. This opens a novel 
therapeutic window to address VEGFA mediated angiogenesis in cancer that is different 
from the dominant HIF1 pathway as well as the IRE1α-XBP1-ATF6α mode of 
regulation. 
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Materials and Methods 
Cell culture  
The hepatocellular carcinoma cell line, HepG2, was obtained from ATCC and 
cultured in MEM with supplements according to ATCC cell culture instructions. Perk-/- 
and Atf4-/- mouse embryonic fibroblasts were gifts from Dr. David Ron (New York 
University School of Medicine) and maintained in DMEM 10% FBS.  Human embryonic 
kidney 293T cells and mouse neuro2a cells were obtained from ATCC and maintained in 
DMEM with 10% FBS.  
Plasmids 
Mouse ATF4, mouse XBP1-processed (Xbp-1-p) and mouse PERK plasmids 
were provided by Dr. David Ron (New York University School of Medicine).  
Lentivirus system 
Lentivirus expressing mouse PERK were generated by subcloning mouse PERK 
into lentiviral expression plasmid, pLenti-CMV/TO (Dr. Eric Campeau at the University 
of Massachusetts Medical School). Lentivirus was produced in HEK293T cells by 
transfection using Lipofectamine2000 (Invitrogen Carlsbad, CA). Lentiviral supernatant 
was collected 48 hours after transfection, and stored at -80 °C. Lentiviral vectors are 
based on modified Gateway technology (Invitrogen Carlsbad, CA) (205). Perk-/- cells 
were infected with mouse PERK lentiviral supernatant and selected with puromycin (2 
μg/ml) to generate stable cell lines.  
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siRNA and plasmid transfection 
Small interfering RNA (siRNA) was transfected using the Cell Line 
NucleofectorTM Kit V and the Nucleofector Device (Amaxa Biosystems, Gaithersburg, 
MD) program T-028 into HepG2 cells. SiRNAs directed against human PERK and 
human ATF4 were synthesized by IDT (Coralville, IA): for human PERK: 
CCAGAGAAGTGGCAAGAAA; for human ATF4: GCAAAGAGCTGGAAAAGAA. 
Cells were incubated in media overnight after siRNA transfection, and then put under ER 
stress.  
Western blotting 
Lysates were extracted using NE-PER® Nuclear and Cytoplasmic Extraction 
Reagents (Pierce Biotechnology, Rockford, IL) supplemented with protease inhibitors. 
Lysates were normalized for total protein (20 μg per lane) for nuclear extracts and total 
protein (50 μg per lane) for cytoplasmic extracts and separated using 4%-20% linear 
gradient SDS-PAGE (Bio Rad, Hercules, CA) and transferred to a nitrocellulose 
membrane. After blocking for 1h at room temperature in TBS-T with 5% nonfat dry milk, 
membranes were incubated at 4°C overnight in TBS-T with 5% nonfat dry milk 
containing a 1:1000 dilution of antibody and washed 3 times with TBS-T. The 
membranes were then incubated for 1 h at room temperature in TBS-T with 5% nonfat 
dry milk containing a 1:3000 dilution of secondary IgG antibody (Cell Signaling, 
Danvers, MA) coupled to horseradish peroxidase (HRP), followed by washing 3 times 
with TBS-T. Immunoreactive bands were visualized by incubation with enhanced 
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chemiluminescence (ECL) (Pierce, Rockford IL) and exposed to x-ray film.  Anti-ATF4 
(anti-CREB-2 H-290), anti-CHOP and anti-actin antibodies were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-PERK antibody was obtained from Cell 
Signaling (Danvers, MA).  
Quantitative polymerase chain reaction 
 Total RNA was isolated from the cells by using the RNeasy Mini Kit (Qiagen, 
Valencia, CA). 1 μg of total RNA from cells was reverse transcribed with Oligo-dT 
primer (Promega, Madison, WI). For the thermal cycle reaction, the iQ5 system (BioRad, 
Hercules, CA) was used at 95°C for 10 min, then 40 cycles at 95°C for 10 sec, and at 
55°C for 30 sec. The relative amount for each transcript was calculated by a standard 
curve of cycle thresholds for serial dilutions of cDNA sample and normalized to the 
amount of the house-keeping beta-actin levels.  The polymerase chain reaction (PCR) 
was performed in triplicate for each sample; all experiments were repeated three times.  
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) was used 
for the quantitative PCR. PCR primer sequences are listed in following table: 
Species Gene Forward Sequence 5'-3' Reverse Sequence 5'-3' 
Mouse Actin GCAAGTGCTTCTAGGCGGAC AAGAAAGGGTGTAAAACGCAGC 
Mouse  Vegfa TGAAGCCCTGGAGTGCGT AGGTTTGATCCGCATGATCTG 
Mouse Atf4 GGGTTCTGTCTTCTCCA AAGCAGCAGAGTCAGGCTTC 
Mouse Spl. Xbp1 CTGAGTCCGAATCAGGTGCAG GTC CATGGGAAGATGTTCTGG 
Mouse Chop CCACCACACCTGAAAGCAGAA AGGTGAAAGGCAGGGACTCA 
Human  GAPDH TGTTCGACAGTCAGCCGC GGTGTCTGAGCGATGTGGC 
Human  VEGFA CCTTGCTGCTCTACCTCCAC ATGATTCTGCCCTCCTCCTT 
Human  PERK CCTCACCATTTGCCTAAGGA GGGGGACTTTCCTTCTTCTG 
Human  ATF4 GTTCTCCAGCGACAAGGCTA ATCCTCCTTGCTGTTGTTGG 
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Luciferase assay 
Mouse VEGFA 3.3Kb intron (460 bp exon 1 + 2891bp intron 1) was cloned from 
mouse BAC clone RP23 (Invitrogen, Carlsbad, CA) into Xho1/HindIII site of pGL3 
luciferase vector (Promega, Madison, WI). 293T cells were transfected with reporter as 
well as mock pGL3 vector along with ATF4 and processed-XBP1 by Lipofectamine™ 
2000 (Invitrogen, Carlsbad, CA). Twenty-four hrs post-transfection, lysates were 
prepared using a Luciferase Assay System kit (Promega, Madison, WI) according to the 
manufacturer’s protocol. The light produced from the samples was read by a standard 
plate reading luminometer. Each sample was read in triplicate and normalized against the 
signal produced from mock wells. β-galactosidase activity was measured by β-Gal 
Reporter Gene Assay, chemiluminescent (Roche Diagnostics, Mannheim, Germany). The 
assay was performed independently three times.  
Chromatin immunoprecipitation (ChIP) 
Mouse neuro2a cells were treated with or without thapsigargin (1 μM) for 6 hrs 
and fixed in 1% formaldehyde. ChIPs were performed using SimpleChIP™ Enzymatic 
Chromatin IP Kit (Agarose Beads) (Cell Signaling, Danvers, MA) as per the 
manufacturer’s recommendation. Anti-ATF4 antibody from Santa Cruz Biotechnology 
(Santa Cruz, CA) and negative control rabbit IgG antibody were used for the ChIP assay. 
Purified DNA from cross-linked cells was dissolved in 50 μl TE; 2 μl was used for PCR. 
Inputs consisted of 10% chromatin before immunoprecipitation. Quantitative PCRs were 
performed as described in the Quantitative polymerase chain reaction section using the 
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following primer set for mouse VEGFA intron 1; forward: 
GCCACAGTGTGACCTTCAGA and reverse: CGTGGAGAAAGGGAACAGAA. 
ELISA 
WT, Perk-/- , and Perk-/- PERK rescued mouse embryonic fibroblasts were treated 
with media without glucose for either 24 hrs or 48 hrs. Both supernatant medium as well 
as whole cell lysates were collected. Mouse VEGF secreted protein from supernatant and 
lysates were measured via ELISA analysis using Bio-Plex 200 System (BioRad, 
Hercules, CA) at the UMass Mouse Phenotyping Center at the University of 
Massahusetts Medical School, Worcester, MA. 
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Results 
PERK is required for VEGFA expression under ER stress 
Previous studies showed that the PERK-ATF4 pathway of the UPR is involved 
the progression of solid tumors. We observed that VEGFA mRNA expression levels are 
upregulated in different tumor cell lines under ER stress conditions. Also, our observation 
that the IRE1-XBP1 pathway is involved in VEGFA upregulation under ER stress 
conditions prompted us to ask whether PERK also affects VEGFA mRNA levels under 
various ER stress conditions. Hence we measured VEGFA mRNA expression levels in 
wild-type and Perk-/- mouse embryonic fibroblasts (MEFs) after treating them with 
thapsigargin (Tg, 1 μM) for 6 hrs (Figure 3.1A). We also treated the cells with media 
deprived of glucose for 24 hrs. These conditions of nutrient deprivation are known to 
cause ER stress (Figure 3.1B). In both cases, we found that VEGFA mRNA expression 
levels are significantly reduced in Perk-/- MEFs as compared to WT MEFs. This result 
shows that PERK must play a role in VEGFA upregulation under different ER stress 
conditions. 
 We then asked the question whether this attenuation of VEGFA expression under 
ER stress conditions is due to lack of PERK exclusively. We transduced the Perk-/- cells 
with lentivirus expressing mouse PERK cDNA and created a stable rescued Perk-/- cell 
line expressing PERK. To confirm that ectopically expressed PERK was functional, we 
treated the rescued cells along with wild-type and Perk-/- parental cells with thapsigargin 
and measured ATF4 and CHOP protein expression, two proteins regulated by PERK. As 
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expected, ATF4 and CHOP protein expression levels were restored in the rescued cells as 
seen in immunoblots of nuclear extract from cells treated with thapsigargin (Tg, 1 μM) 
for 5 hrs. PERK protein levels are shown in immunoblot of cytoplasmic extracts from the 
same cells (Figure 3.2A). When mRNA expression levels were analyzed, we found that 
PERK expression was rescued in the Perk-/- cells and the PERK-ATF4 pathway was fully 
functional with the restoration of ATF4 mRNA levels as well as protein levels of both 
ATF4 and CHOP. VEGFA mRNA expression levels were also restored to wild-type 
levels under ER stress conditions in the recued cells (Figure 3.2B).  
To determine whether PERK-mediated regulation of VEGFA expression affected 
expression of VEGF protein levels as well as its secretion outside the cell, we treated 
wild-type, Perk-/-  as well as the Perk-/- rescued with PERK MEFs with media lacking 
glucose. Nutrient deprivation causes ER stress and can upregulate VEGFA as seen in 
Figure 3.1B. Analysis of cell protein lysate and supernatant VEGF protein reveals that 
expression as well as secretion of VEGF was restored in the rescued cells (Figure 3.3). 
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Figure 3.1. ER stress induced VEGFA upregulation is dependent on PERK. (A) WT 
and Perk-/- MEFs were treated with thapsigargin (Tg, 1 μM) for 6 hrs, and also treated with (B) 
media with or without glucose for 24 hrs. Total RNA was collected and VEGFA expression 
levels were measured by quantitative PCR (n=3, values are mean ± SD). 
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Figure 3.2. PERK is essential and sufficient for ER stress-mediated VEGFA mRNA 
upregulation. (A) Perk-/- MEFs were stably transduced with LV/PERK, a lentivirus 
constitutively expressing PERK. These cells along with WT and Perk-/- MEFs and treated with 
thapsigargin (Tg, 1μM) for 5 hrs. Cytoplasmic protein lysates were extracted and analyzed by 
immunoblot using anti-PERK antibody. Nuclear protein lysates were analyzed by immunoblot 
using anti-ATF4 and anti-CHOP antibodies to show rescue of PERK signaling pathway. (B) Total 
RNA from the above treated MEFs was analysed for VEGFA and ATF4 expression levels (n=3, 
values are mean ± SD). 
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Figure 3.3. PERK is required for VEGF protein synthesis and secretion under ER 
stress. WT, Perk-/- and Perk-/- rescued MEFs were kept in media with or without glucose for 0, 
24 and 48 hrs. Supernatant medium as well as whole cell lysates were collected and analyzed for 
VEGF protein concentration by ELISA. 
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PERK mediates VEGFA upregulation under ER stress via ATF4 
VEGFA has been shown to be transcriptionally upregulated under oxidative stress 
conditions induced by arsenite, hydrogen peroxide and superoxides (197, 212), and this is 
mediated by activation of ATF4 (197). This study also revealed that the UPR is not 
activated under oxidative stress conditions induced by arsenite treatment. ATF4 
activation occurs due to eIF2α phosphorylation by the eIF2α kinase HRI and not PERK 
(197). However, ATF4 translation is dependent on PERK signaling under ER stress 
conditions (63, 65). These considerations prompted us to investigate the role of ATF4 in 
VEGFA mRNA expression under ER stress conditions. We measured VEGFA mRNA 
expression in Atf4-/- MEFs and wild-type MEFs. We found that VEGFA mRNA levels 
were attenuated in Atf4-/- cells as compared to wild-type cells under ER stress induced by 
thapsigargin. CHOP downregulation confirms that ATF4-mediated UPR signaling is 
suppressed in Atf4-/- MEFs under ER stress (Figure 3.4). These results show that ATF4 is 
required for VEGFA upregulation under ER stress conditions. To further confirm the role 
of the PERK-ATF4 pathway in VEGFA mRNA induction, we transfected hepatocellular 
carcinoma cell line, HepG2, with siRNAs directed against PERK and ATF4 and then 
measured VEGFA mRNA expression under ER stress conditions. RNAi-mediated 
knockdown of PERK (Figure 3.5A) and ATF4 (Figure 3.5B) in HepG2 cells resulted in a 
significant decrease of VEGFA mRNA expression. Significant ATF4 knockdown in 
PERK-deficient cells suggests that ATF4 has a role in PERK-mediated VEGFA 
regulation.  
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Figure 3.4. ER stress-mediated VEGFA upregulation is dependent on ATF4. Atf4-/- 
MEFs were treated with thapsigargin (Tg, 1 μM) for 4 hrs. Total RNA was collected and 
expression levels of VEGFA and CHOP were measured by quantitative PCR (n=3, values are 
mean ± SD).  
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Figure 3.5. PERK upregulates VEGFA expression via ATF4. (A) HepG2 cells were 
transfected with scramble (Control) and PERK siRNA. 18 hrs post-transfection, cells were treated 
with thapsigargin (Tg, 1 μM) for 4 hr. Total RNA was collected and VEGFA, PERK and ATF4 
expression levels were measured by quantitative PCR (n=3, values are mean ± SD). (B) HepG2 
cells were transfected with scramble (Control) and ATF4 siRNA and treated with thapsigargin 
(Tg, 1 μM) for 4 hr. Total RNA was collected and VEGFA and ATF4 expression levels were 
measured by quantitative PCR (n=3, values are mean ± SD). 
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ER stress-mediated VEGFA upregulation involves partial cross-talk between 
PERK-ATF4 and IRE1-XBP1 signaling 
The IRE1-XBP1 pathway has been proposed to have a role in ER stress-induced 
VEGFA mRNA expression. As previously mentioned, redundancy of the UPR response 
to ER stress is maintained by considerable cross-talk between downstream effectors of 
the UPR. As Atf4-/- MEFs show attenuation of VEGF-A expression under ER stress, it 
suggests that the redundancy between IRE1-XBP1 pathway and PERK-ATF4 pathway is 
not sufficient to maintain normal VEGF-A levels. To determine whether there is any 
change in spliced XBP1 levels that might contribute to VEGF-A attenuation in these 
cells, we looked at spliced XBP1 mRNA levels in Atf4-/- cells treated with thapsigargin 
for 4 hrs. Absence of ATF4 does not seem to have any impact on spliced XBP1 levels in 
these cells suggesting that ATF4 is essential for maintenance of normal VEGFA 
expression levels (Figure 3.6A). Conversely, when we looked at Ire1α-/- MEFs treated 
with thapsigargin, we found that ATF4 mRNA levels do not show any significant 
attenuation even though VEGFA levels are attenuated in these cells (Figure 3.6B). This 
suggests that both pathways might be regulating VEGFA independently of each other 
under ER stress. We then asked the question, what happens when both PERK and IRE1 
are downregulated? We transfected HepG2 cells with IRE1 and PERK siRNAs and found 
that VEGFA is attenuated by almost 50% in both cases. Interestingly, when IRE1 and 
PERK siRNAs are transfected together in equal amounts, VEGFA expression levels are 
attenuated by almost 75%, as compared to control siRNA cells (Figure 3.7). These 
findings suggest that PERK-ATF4 pathway and IRE1-XBP1 pathway are both crucial for 
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normal VEGFA expression levels under ER stress conditions and they appear to be 
independently regulating VEGFA. As we already determined how XBP1 might be 
regulating VEGFA expression, we thus became interested in determining how exactly 
ATF4 might be regulating VEGFA. 
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Figure 3.6. ATF4-mediated VEGFA upregulation is independent of XBP1 splicing 
and vice-versa. (A) WT and Atf4-/- MEFs were treated with thapsigargin (Tg, 1 μM) for 4 hrs. 
Total RNA was collected and expression levels of spliced XBP1 and VEGFA were measured by 
quantitative PCR (n=3, values are mean ± SD). (B) WT and Ire1α--/- mouse embryonic fibroblasts 
(MEFs) were treated with thapsigargin (Tg, 1 μM) for 5 hr. Total RNA was collected and ATF4, 
VEGFA and spliced XBP1 expression levels were measured by quantitative PCR (n=3, values are 
mean ± SD). 
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Figure 3.7. Double knockdown of IRE1 and PERK results in greater attenuation of 
VEGFA expression. HepG2 cells were transfected with scramble (Control), IRE1 and PERK 
siRNA. 18 hrs post-transfection, cells were treated with thapsigargin (Tg, 1 μM) for 4 hr. Total 
RNA was collected and VEGFA expression levels were measured by quantitative PCR (n=3, 
values are mean ± SD). 
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ATF4 regulates VEGFA by binding intron 1 of mouse VEGFA gene 
ATF4 has been previously shown to interact with the first intron of the human 
VEGFA gene under oxidative stress conditions caused by arsenite treatment. ATF4 
interacts with an amino-acid response element (AARE) present in the intron ‘AsnSyn’ 
site at +1767 bp of the human VEGF gene (197, 213). We therefore considered the 
possibility that ATF4 binds to the first intron of the mouse VEGFA gene under ER stress 
conditions. To confirm the results in human VEGF analysis, a gene fragment carrying a 
3.3 Kb fragment of intron 1 (2.8 Kb intron 1 + 0.5 Kb exon 1) of the mouse VEGFA gene 
was cloned into pGL3 luciferase vector. When this reporter was transfected along with 
ATF4 and XBP1-processed (XBP-1-p) plasmid into cells, we observed that ectopic ATF4 
expression, but not XBP-1-p, increased the luciferase activity of the reporter (Figure 3.8). 
This suggests that ATF4 must be binding the VEGFA intron in a similar manner as it 
does under oxidative stress by arsenite or oxidative phospholipids. 
In order to test whether ER stress promotes binding of ATF4 to the intron of 
mouse VEGFA gene, we conducted chromatin immunoprecipitation (ChIP) analysis of 
the mouse VEGFA intron. Presuming a functional analogy with the human VEGFA 
intron, we used PCR primers starting from +1581bp of the 2891 bp intron to yield a 109 
bp product for ChIP analysis of mouse neuro2A cells. Treatment of neuro2A cells with 
thapsigargin for 6 hrs revealed that ATF4 was recruited to the VEGFA intron 1 under ER 
stress (Figure 3.9). Collectively, these results indicate that the PERK-ATF4 pathway 
directly regulates VEGFA mRNA expression through intron 1 of VEGFA gene under ER 
stress conditions. 
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Figure 3.8. Mouse VEGFA intron 1 reporter is activated by ATF4. Upper panel shows 
schematic of mouse VEGFA gene as well as size of mouse VEGFA-intron construct which 
consists of 0.5Kb exon 1 and 2.8 Kb intron 1 fused to luciferase gene in pGL3 vector. Luciferase 
activity in 293T cells transfected with mouse VEGFA-intron 1 reporter (pGL3/VEGF0/+3351) or 
control pGL3 mock constructs along with indicated proteins and control PCDNA3 vector (values 
are mean ± SD). 
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Figure 3.9. ATF4 binds VEGFA intron 1 under ER stress. Chromatin IP was performed 
using anti-ATF4 antibody or control anti-IgG antibody in mouse neuro2a cells treated with or 
without thapsigargin (Tg, 1 μM) for 6 hrs. Quantitative PCR of ChIP products was used to 
analyze recruitment of ATF4 to VEGFA intron. PCR primers corresponded to mouse VEGFA-
intron 1 genomic region. Fold enrichment was quantified using ratio of amplification of PCR 
product relative to 10% input DNA. Value obtained from mock was defined as 1 (n=3, values are 
mean ± SD).   
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Discussion 
The PERK-eIF2α-ATF4 pathway has been suggested to have a role in hypoxia 
resistance and tumor growth. Studies from the Koumenis lab have shown that PERK 
inactivation and blocking of the translation initiation factor, eIF2α leads to increased 
sensitivity and decreased tumor size and cell survival. These studies showed that the 
PERK pathway is activated in the hypoxic areas of the tumor, and its activity is critical 
for survival (150). Hypoxic stress in tumors has been found to activate PERK resulting in 
general translational inhibition and specific upregulation of pro-survival arm including 
ATF4 (148). It has also been shown that hypoxia-responsive genes have internal 
ribosomal entry elements (IRES) to maintain their translational priority, some of which 
are: platelet-derived growth factor (PDGF), VEGF and HIF1α all of which help the tumor 
cells survive the harsh conditions (108, 185, 214). The presence of unusually long 
5’UTRs and IRES make these genes amenable to control by various transcriptional 
programs which are specific to different kinds of stress. One of those stress responsive 
programs is the unfolded protein response (UPR). Even though hypoxia is a primary 
mediator of angiogenesis in tumor cells, previous studies have shown the importance of 
HIF1-independent regulation. One study reveals how PERK mediates its effect on tumor 
cells by regulating the pro-angiogenic type 1 collagen inducible protein (VCIP) under 
hypoxic conditions (151). Our studies clearly show how the PERK-ATF4 pathway 
regulates VEGFA which in turn helps in angiogenesis. 
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A DNA microarray of Perk-/- MEFs treated with hypoxia revealed that VEGFA 
might be a potential candidate that is downregulated in these cells (151). However, the 
mechanism employed for activating VEGFA via the PERK-mediated pathway has not 
been established yet. We show here that PERK is required for VEGFA upregulation 
under ER stress and it regulates VEGFA expression through its downstream effector 
ATF4.  
Previous studies revealed that different cellular stresses like amino-acid 
deprivation and oxidative stress activate different kinases namely GCN2 and heme-
regulated inhibitor (HRI) which can upregulate the downstream effector ATF4. The 
upstream kinases respond to specific kinds of stress and are not activated under any other 
stresses. For example; amino-acid stress mediated GCN2 activation causes eIF2α 
phosphorylation and ATF4 upregulation, however PERK activity is not required under 
this kind of stress (63). ATF4, under oxidative stress has been shown to bind the human 
VEGFA intron. This observation made us ask whether the same strategy is employed by 
PERK under ER stress conditions. We found here that ATF4 indeed binds the mouse 
VEGFA intron under ER stress. We had observed previously that spliced active XBP1 is 
able to bind the VEGFA promoter.  
Hence, our findings suggest that the PERK-eIF2α-ATF4 pathway represents a 
second modulatory pathway of VEGFA which is distinct from IRE1-XBP1 pathway. We 
also observed that attenuation of VEGFA caused by inactivation of PERK is not restored 
fully by the other pathway which remains active (Figure 3.6). The converse is also true. 
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PERK-ATF4 pathway is not able to restore VEGFA expression to wild-type levels in 
Ire1-/- cells. This, however does not rule out crosstalk between the two pathways to 
control VEGFA as will be explained by observations in the next paragraph. Our results 
suggests the VEGFA regulation requires the simultaneous activation of both pathways in 
order to maintain its expression and synthesis under ER stress conditions. This hypothesis 
was further supported by our observation in the siRNA transfected HepG2 cells. We 
found that when cells are transfected with both IRE1 and PERK siRNAs, the combined 
knockdown effect is even more drastic on VEGFA expression (Figure 3.7). This further 
confirms that the UPR is essential for VEGFA regulation. It also suggests that when both 
arms of the UPR are targeted the effect is stronger. Hence, it would be interesting to 
study the effect of inhibitors of both PERK and IRE1 pathways on VEGFA expression in 
cells. 
It is important to note that the Perk-/- MEFs had a stronger VEGFA attenuation 
than the PERK siRNA transfected cells under ER stress. This might be due to level of 
PERK knockdown in the siRNA transfected cells not being the same as in the knockout. 
This observation of stronger knockdown is only specific to the knockout MEFs. The 
absence of PERK might be able to bring down IRE1 expression too in these cells and 
therefore we see a stronger knockdown in VEGFA in these cells than in PERK siRNA 
treated cells. Further studies are required to fully elucidate the level of crosstalk between 
different UPR sensors under ER stress and their effect on VEGFA expression. 
 
133 
 
 
Thus based on our findings in chapter III we propose a model for the role of the 
PERK-ATF4 pathway in angiogenesis. When ER stress occurs due to adverse 
environmental conditions like hypoxia and nutrient glucose deprivation, the activation of 
PERK leads to preferential upregulation of ATF4. ATF4 then binds the first intron of 
VEGFA gene and upregulates VEGFA expression which then drives angiogenesis 
(Figure 3.10). 
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Figure 3.10. PERK upregulates VEGFA under ER stress. Proposed model shows the 
activation of VEGFA intron by PERK-ATF4 signaling to upregulate VEGFA expression under 
ER stress. 
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The unfolded protein response signaling network of the ER has been implicated in 
the maintenance of various cellular functions like protein folding, degradation of 
misfolded proteins, maintenance of calcium homeostasis and redox balance, cell fate 
determination, differentiation and gene regulation in general. In this thesis we have been 
able to characterize the role of UPR in direct transcriptional regulation of angiogenesis, a 
crucial mediator of cell growth and survival.  
Defects in the UPR have been found in several disease states, like 
neurodegeneration, diabetes, heart disease, obesity and cancer. According to the latest 
2009 US mortality numbers, about 50% of all deaths in the US are due to either cancer or 
heart disease. This makes the study of all possible signaling pathways and avenues for 
therapeutic intervention imperative in order to tackle these diseases. As angiogenesis is a 
crucial event in cancer growth as well as normal blood vessel development, our studies 
provide a novel insight into its mechanism and thus open a window of opportunity to 
look for novel therapeutic agents. Our studies reveal the mechanism of the regulation of 
VEGFA, a key regulator of angiogenesis, by the UPR.  
VEGFA protein and its receptor VEGFR-2, plays a pivotal role in normal and 
pathological angiogenesis not only in the context of tumor vascularization but also in 
normal embryonic and placenta development. In both cases, growing cells rapidly 
outstrip the supply of nutrients leading to ER stress and activation of the UPR (160). 
VEGFA expression plays essential role in multiple cellular processes that ultimately lead 
to cell permeability, migration, mitogenesis, differentiation and survival (161). VEGFA 
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overexpression has been correlated with tumor progression in several cancers which grow 
very fast and develop a hypoxic and nutrient deficient environment and need VEGFA to 
sustain their requirements. Not only in cancer, but in normal development also, 
angiogenesis is essential for decidualization, development of vascular membranes, 
placenta formation and organogenesis (195).  
Placenta formation is crucial as it is vital for the survival of the mammalian 
embryo in the uterine environment. The mature placenta in mice is established by 
embryonic day 10 and is composed of three principal layers: an outer layer of trophoblast 
giant cells, a middle spongiotrophoblast layer and the innermost labyrinth (Figure 2.1). 
The placenta is an interface between the fetus and the mother and is an important source 
of pregnancy-associated hormones and growth factors and is also involved in the immune 
protection of the fetus. Angiogenic growth factors like angiopoietin and VEGF are 
among the large number of growth factors and structural proteins produced in the 
placenta which are required by the growing fetus (195). Therefore, it is only natural that 
ER stress occurs in the placenta thereby evoking a strong UPR (160). Our data show that 
ER stress signaling is indeed active and IRE1α plays a major role in the expression of 
VEGFA in the labyrinthine placenta. Insufficient vascularization due to defective 
trophoblast blood vessel formation is found in VEGF knockout animals. Recent work in 
2009 by the Kohno lab had shown that IRE1α function is necessary for placental 
development (194). However, they were not able to show which layer develops the 
placenta defect using tissue sections. Our results in the placenta cell line SM10 nicely 
complement their findings and show that IRE1α is required for VEGFA expression and 
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thus regulates proper development and morphogenesis of blood vessels in the 
labyrinthine layer of the growing placenta and hence is essential for embryonic viability. 
 As mentioned earlier, the primary regulator of VEGFA expression is the hypoxia 
inducible factor, HIF1α.  HIF1α has been shown to be involved in placental growth and is 
required for expression of VEGF and endothelial cell specific response genes (201). Our 
studies reveal that along with hypoxic signaling, the UPR is also required in these cells 
for normal expression of VEGFA as HIF1α knockdown does not seem to regulate 
VEGFA under ER stress specifically. ER stress in the developing placenta is probably a 
combination of hypoxic stress along with nutrient and glucose deprivation, all of which 
create a stressful environment for the growing embryo and hence the UPR becomes 
essential for development.  
Though IRE1α is essential for normal labyrinth development, XBP1 deficiency 
alone however does not lead to a defective placenta phenotype or lower VEGF levels in 
some cancer cell lines under only hypoxic conditions. XBP1 knockout animals are 
embryonic lethal and die of fetal liver hypoplasia (13, 196). Our results suggest that 
IRE1α-mediated VEGFA expression is essential for the development of the labyrinthine 
placenta and for embryonic viability. This discrepancy in phenotypes of the labyrinthine 
placenta and tumor VEGF levels may be due to two reasons. First, the unspliced form of 
XBP1 (XBP1u) might have a role in the lethal phenotype of Ire1α-/- animals. XBP1u is 
constitutively expressed and translated in mammalian cells and has been shown to bind 
both XBP1s and cleaved active ATF6α to target it for rapid degradation by the 
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proteasome (215). Cleaved ATF6α also upregulates XBP1 mRNA levels under ER stress 
(31). Therefore, in Ire1α-/- animals, XBP1u protein levels are increased and they are 
successfully able to downregulate ATF6α-mediated VEGFA expression too and hence 
the phenotype is severe. This might also be the reason why ectopic expression of XBP1s 
by itself cannot upregulate VEGFA due to the presence of a large population of XBP1u 
molecules. Only upon ER stress, when the XBP1s population increases dramatically, can 
we see binding and activation of VEGFA mRNA expression. However, in Xbp1-/- 
animals, there is no XBP1u or XBP1s; hence the ATF6α pathway might be compensating 
along with PERK pathway for the loss of XBP1s-mediated VEGFA expression. 
Secondly, studies in Xbp1-/- fibroblasts reveal that these cells have a stronger ER stress 
response and JNK activation than normal wild-type cells suggesting a compensation by 
other UPR mediators as opposed to Ire1α-/- fibroblasts where XBP1s levels are 
downregulated (48). Hence, these two knockout cells are different in their response to ER 
stress. Further in vivo studies in the placenta tissue sections should be able to explain this 
dichotomy in phenotypes.  
It is also interesting to note that the other two regulators of the UPR, PERK and 
ATF6α do not have an embryonic lethal phenotype (62, 84). Cell-specific as well as 
stress-specific upregulation of different UPR regulators has been reported (216). Because 
the UPR response involves different transcription factors, they may involve different 
activation kinetics to allow the ER to choose the ‘best fit’ response to prevailing 
conditions and hence the variance in phenotypes in different cells. This and the Xbp1-/- 
animal phenotype suggests that PERK and ATF6α might have a partial role in the 
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placenta and their absence might be compensated by the well-established function of 
IRE1α. Thus, it becomes clear that IRE1α definitely and specifically plays an essential 
role in the normal development of the placenta and therefore is crucial to survival of the 
embryo. 
PERK-mediated VEGFA regulation occurs via binding of ATF4 to the VEGFA 
intron under ER stress conditions. Previous studies had revealed that PERK is required 
for resistance to hypoxia-induced apoptosis and also contributes to tumor growth (150). 
PERK is part of a group of eIF2α kinases which phosphorylate eIF2α to regulate protein 
translation under different kinds of stress like ER stress, oxidative stress, viral infection, 
amino acid deprivation etc. (63). These different kinases can however converge on the 
specific preferential activation of their downstream effector, ATF4, to upregulate stress-
responsive genes. Our results indicate that like oxidative stress-mediated GCN2-ATF4 
activation of VEGFA, ER stress can also activate VEGFA via activation of the PERK-
ATF4 pathway.  
However, in 2005, the Koumenis lab had reported that under hypoxic conditions 
wild type and non-phosphorylatable eIF2α mutant (S51A) cells had similar VEGF 
secretion levels (150). This was contrary to our finding where Perk-/- MEFs had much 
lower levels of secreted VEGF protein as compared to wild-type MEFs under glucose-
deprivation induced ER stress. This discrepancy in response to different types of stress 
again points to the fact that a different kind of stress put on a cell will elicit a different 
response. Under only specific hypoxic conditions, HIF1α signaling takes over VEGFA 
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regulation and thus may be compensating for attenuated PERK-ATF4-mediated VEGFA 
regulation in the mutant S51A cells. Under glucose deprivation or under ER stress 
induced by thapsigargin, PERK-ATF4-mediated VEGFA regulation becomes necessary 
while HIF1α does not as the HIF1α protein is unstable under normoxic conditions. To 
test this, we treated wild-type and Perk-/- MEFs with both hypoxia and glucose 
deprivation simultaneously. We were not able to get any live cells to measure VEGFA 
expression levels (data not shown). Hence we can deduce that within the tumor, where 
both HIF1α and PERK-ATF4 signaling are active, VEGFA expression and secretion 
levels must be under the control of both regulatory networks. 
When we started this project, VEGFA regulation was and still is thought to be 
primarily through the hypoxia inducible factor, HIF1α which is functional only under 
hypoxic conditions. HIF1α is the primary target of most of the research being currently 
conducted on angiogenesis especially in tumors. The hypoxia response element (HRE) 
present in VEGFA promoter was also found in other genes regulated by HIF1α, all of 
which form part of the hypoxia signaling which helps in growth of blood vessels and 
tumor survival under hypoxic conditions. HIF1-independent regulation primarily consists 
of VEGFA mRNA stabilization through the 3’UTR via activation of stress-activated 
protein kinases like JNK and p38 by the stressful tumor environment (193). Our results 
show that the ER stress signaling or UPR forms a crucial HIF1-independent regulatory 
mechanism for expression of VEGFA. This regulation is independent of post-
transcriptional mRNA stabilization. Our studies reveal that the unfolded protein response 
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or ER stress signaling is a vital regulator of VEGFA expression which is independent of 
hypoxic signaling. 
The regulation of VEGFA is two-pronged under ER stress. ER stress activates 
IRE1α and ATF6α which in turn activates spliced XBP1 and cleaved ATF6α which both 
bind the VEGFA promoter. ER stress also activates PERK which in turn activates ATF4 
which binds VEGFA intron (Figure 4.1). Our findings reveal that the activity of all three 
regulators is required to maintain the increased VEGFA mRNA levels under ER stress. 
The fact that when the PERK and IRE1α pathways are knocked down simultaneously, 
VEGFA attenuation is more severe, suggest that under some cases (specific cells or 
tissues) all three regulators may be required simultaneously to express VEGFA under ER 
stress. 
 Our observation that cleaved ATF6α and XBP1s both bind the VEGFA promoter 
is supported by earlier studies that show that these two molecules can heterodimerize 
efficiently to activate downstream regulators. Thus our study reveals the novel function 
of ATF6α in VEGFA regulation under ER stress and points its contribution towards 
angiogenesis. Further studies in Atf6α-/- cells and tumors will reveal its effect on VEGFA 
protein synthesis and secretion.  
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Figure 4.1. Model of UPR-mediated regulation of VEGFA. ER stress activates IRE1α-
XBP1, ATF6α and the PERK-ATF4 signaling pathways to upregulate VEGFA expression which 
is essential for normal and pathological blood vessel development. 
 
 
 
 
144 
 
 
The mammalian UPR has been proposed to have a time-dependent response to 
accumulation of unfolded proteins in the ER. ATF6-mediated ER quality control involves 
activation of chaperones that help in refolding of misfolded or unfolded nascent proteins, 
thereby mediating a ‘unidirectional’ phase. Prolonged ER stress leads to activation of 
XBP1 and dimerization with ATF6 to activate ERAD components along with refolding 
thereby starting the ‘bi-directional’ phase (217). The PERK-eIF2α pathway signals the 
translational inhibition first and then turns on the translation of downstream effectors 
preferentially through activation of alternate ORFs on ATF4. All these manipulations are 
part of a broad strategy to pull off a robust response to the accumulation of unfolded 
proteins due to various kinds of ER stress occurring in a cell.  
The requirement of all three master regulators for proper expression of VEGFA 
suggests that the cells attach special importance to its expression throughout the entire 
time that ER stress is occurring. Multiple regulatory modes give these regulators potent 
control over VEGFA expression. This tight regulation also gives us a nice opportunity to 
manipulate VEGFA expression by modulating the UPR regulators. Inactivation or 
knockdown of each regulator causes VEGFA attenuation under ER stress, and when two 
pathways are simultaneously knocked down, the attenuation of VEGFA is more 
pronounced. Hence inhibitors that can target multiple UPR regulators should be able to 
cripple tumor angiogenesis robustly. Hence, our studies reveal a novel therapeutic 
opportunity to target angiogenesis farther upstream in the molecular pathway than the 
current drugs that mostly target VEGF receptor signaling. 
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Already, some components of the UPR pathway are targets of therapeutic drugs. 
For example, Versipelostatin targets BiP upregulation (141), proteasome inhibitor 
Velcade (Bortezomib) overloads the UPR by targeting ERAD pathway in multiple 
myeloma (47), HIV protease inhibitor, Nelfinavir induces ER stress-mediated apoptosis 
in C6 glioma and non-small-cell lung cancer cells by inducing BiP and CHOP (218) and 
brefeldin A which can again induce BiP and CHOP to mediate apoptosis in leukemic B 
cells (219).  
Anti-angiogenic therapy consists of the anti-VEGF antibody Bevacizumab, and 
the multi-targeted receptor tyrosine kinase inhibitors (RTKIs) Sunitinib and Sorafenib 
which target downstream VEGFA receptor signaling pathways (220). These anti-
angiogenic drugs have helped in lengthening the lives of numerous cancer patients. 
However, recent clinical studies have shown that even though VEGF-therapy targets 
primary tumor growth, eventually they shorten survival of mice by promoting tumor 
invasiveness and metastasis. This might be due to adaptation via different angiogenic 
programs, development of resistance to hypoxia, activation of alternate growth factors 
and cytokines by tumor cells, VEGF induction by stromal cells (220, 221). These 
observations suggest that the current angiogenic therapy needs to be complemented with 
new therapeutic agents which will target upstream pathways so as to minimize the 
chances of adaptation to one regimen. Because IRE1α and PERK are kinases and 
together with ATF6α are ER transmembrane proteins all activated by conformational 
changes due to binding and release of chaperones like BiP, this property makes them 
‘druggable’ i.e. they can be targeted by small molecules. Thus they are definitely 
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promising targets for therapeutics to block UPR signaling directly in order to control the 
expression of VEGFA and therefore blood vessel growth in ER stress sensitive regions 
like growing tumors. 
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